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ABSTRACT
Iron is an integral part of hemoglobin and essential for the production of red blood cells.
Iron deficiency and the resulting anemia aremajor nutritional deficiency disorders. The majority
of patient populations suffering from iron deficiency anemia (IDA) are women of child bearing
age and children of all ages. Iron deficiency is a complication of various other chronic
conditions.
Oral iron salts or colloidal parenteral iron formulations are treatment options for iron
replenishment since several decades, but they are associated with severe side effects along with
other patient noncompliance issues. Transdermal delivery of iron could be a potential alternative
to treat iron deficiency due to safety and offers more acceptability.Since conventional iron
formulations are not suitable for transdermal delivery, quest for an ideal iron compound resulted
in identification of soluble Ferric Pyrophosphate (FPP), whichwas demonstrated to be very stable
and safe for parenteral administration.
Passive delivery of FPP was not successful due to its high molecular weight (~745 Da)
and low lipid solubility.Transdermal delivery of FPP using chemical permeation enhancers,
iontophoresis, microneedle pretreatment and combination of these techniques were evaluated and
proved to be successful in delivering iron across the skin. When iontophoresis was combined
with microneedle pretreatment, adequate iron could be delivered in anemic rat models to reverse
the iron deficiency. Further, a safe and patient friendly iron delivery system was developed by
incorporating FPP in soluble microneedles.In vitro and in vivo studies were carried out to
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evaluate the FPP release and dermal kinetic profile of the iron from the soluble microneedles.
Safety and toxicity of FPP in human skin cell lines was also investigated.
The feasibility of transdermal delivery of Iron-dextran was also evaluated. Passive
delivery of iron dextran is impossible due to its high molecular weight. Microneedle assisted
delivery of iron dextran was investigated and soluble microneedle system with iron dextran was
developed.
Overall, the results of the project suggest that transdermal delivery of iron could be a
potential alternate to treat IDA.Iron replenishment via transdermal route is likely to be more
effective and safer than the conventional routes of administration.
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CHAPTER 1
INTRODUCTION
1.1. Brief history and role of iron in early life
Iron is a ubiquitous transition metal and is the fourth most abundant element present in
the earth's crust. Life on earth started about 3.5 billion years ago in a relatively oxygen-free
atmosphere on the mineral surfaces, such as iron pyrites (FeS2) [1-3]. Nearly three billion years
ago, abundant soluble ferrous iron was available for early life forms, before the introduction of
oxygen in the atmosphere bycyanobacteria via photosynthesis. In the next ~1.5 billion years, the
atmospheric oxygen content increased to approximately 21 % which became toxic to organisms
that were not adapted tooxygen environment. This increase in oxygen resulted in a great
enhancement in the metabolic efficiency (~18 folds) of oxygen-adapted organisms compared to
anaerobic fermentation. The increased oceanic oxygen oxidized soluble ferrous iron to virtually
insoluble ferric iron form. This enormous transformation in the atmospheric oxygen and its
oxidization of ferrous iron made all oxygen respiratory organisms to struggle for acquiring and
storing this valuable metal, iron [1].
1.2. Iron- precious metal for survival
Iron can be considered as the most valuable metal for life on Earth. The typical adult
human body contains an average of 3.5 g of iron (approximately 4 g for males and 3 g for
females). Iron is found in the human body in two forms, as functional iron (iron that serves a
metabolic function) and as storage iron. Iron homeostasis in the system is closely regulated via
intestinal absorption from diet and by recycling of iron from the senescence of aged red blood
1

cells. There is no physiologic mechanism for iron excretion from the body. Only 1 mg of iron is
lost per day by males and 2 mg by menstruating females (through blood and mucosal epithelial
cell loss) [4].
Iron is an essential trace element for cell growth and is the key nutrition element required
for all living organisms [5]. Iron is an integral part of heme and hemoglobin (figure 1-1) and
functions as carrier of oxygen from lungs to tissues. Iron is also present in myoglobin (an
intracellular store of oxygen), in the cytochrome enzymes of the mitochondrial electron transport
chain and in cytochrome P-450, which is involved in the metabolism of drugs and other foreign
materials [6].
Iron can readily accept or donate electrons and this capacity to participate readily in
redox reactions makes, iron a valuable player as catalyst in various biological processes which
participates in oxidation and reduction reactions. Iron is also present in catalase and peroxidase,
which prevents free radical-mediated cell damage; and in a number of other enzymes involved in
energy

metabolism,

such

as

reduced

nicotinamide

adenine

dinucleotidephosphate

dehydrogenase. Iron participates in the biosynthesis of DNA and RNA [7] and it is a constituent
of a number of important macromolecules, including those involved in respiration, oxidative
phosphorylation, and xenobiotic metabolism. Iron helps in the production of connective tissues
and neurotransmitters in brain and useful for neural development [8, 9]. Excess iron
accumulation in the system is harmful and causes organ dysfunction through the production of
reactive oxygen species (ROS).
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Figure 1-1. Molecular structure of heme

1.3. Iron deficiency and anemia
Iron deficiency (ID) develops when body iron (functional iron) is not adequate to meet
the physiological needs for growth and development. As the iron depletion progresses, iron
stores in the system will also get affected and the hemoglobin concentration in red blood cells
falls below the normal range which is referred as iron deficiency anemia (IDA). Iron deficiency
can exist with or without anemia [10, 11]. Iron deficiency anemia is caused by dietary
deprivation and/or poor absorption of iron or may occur due to chronic blood loss. Iron
deficiency is one of the most prevalent and serious health issues among people all over the
world. Iron deficiency anemia is the major contributing factor among all other anemia disorders.
An estimated 2 billion people are suffering from iron deficiency and IDA worldwide with the
majority from developing countries [12, 13 &14].IDA can affect the length and quality of life in
patients and can increase morbidity and mortality.
IDA is the most common prevalent nutritional deficiency disease among children
especially in premature or low birth weight babies and in menstruating, pregnant and lactating
women. IDA is associated with growth retardation and cognitive development in children.IDA, if
3

uncorrected leads to psycho neurological problems in children of all ages and diminished work
productivity and behavioral problems in adults [15, 16]. Patients with IDA have a higher risk of
psychiatric disorders, including unipolar depressivedisorder, anxiety disorder, attention
hyperactivity disorder, delayed development and mental retardation [17].Iron is essential for
normal development of the immune system and IDA can be aggravated by presence of infectious
diseases and vice versa [18, 19 &20].
Menstruating women lose ~1–2.5 mg of iron per day on an average through menstrual
blood loss and a loss of 1-ml blood would translate to a loss of 0.5 mg of iron.The demand for
iron increases several folds in pregnant women to meet the requirements of red blood cell mass
expansion and unidirectional transfer of iron from mother to developing fetus [21, 22].The WHO
estimates that 39% of children younger than 5 years, 48% of children between 5 and 14 years,
42% of all women, and 52% of pregnant women in developing countries are anemic with halfof
them having iron deficiency anemia [22]. According to the WHO, the frequency of iron
deficiency in developing countries is about 2.5 times that of anemia [23].
1.4. IDA and comorbidities
Iron deficiency is a complication of other chronic conditions like renal failure, chronic
kidney disease (CKD), inflammatory bowel disease (IBD), Parkinson’s disease and rheumatoid
disease.Iron deficiency is a common problem in patients with end stage renal disease (ESRD),
particularly in those treated by dialysis, because of impairment in gastrointestinal absorption,
ongoing blood losses andsometimes due to an impaired capacity to mobilize iron from its stores.
The anemia associated with end-stage renal disease is corrected with recombinant human
erythropoietin and administration of erythropoietin leads to rapid utilization of iron for
erythropoiesis. Therefore most dialysis patients require iron supplementation in order to maintain
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responsiveness to erythropoietin stimulating agents (ESAs) [24]. Parenteral iron therapy is the
only option so far for these patients to sustain adequate treatment with erythropoietin-stimulating
agents[25]. Prevalence of IDA in patients with IBD ranged from 9% to 74% [26] and in patients
suffering with Crohn’s disease the IDA prevalence ranged from 6% to 74% [27].
Iron

deficiency

coincided

with

sympathetic

activation,left

ventricular

hypertrophy,dilatation,compromised hemodynamics and symptomatic heart failure [28, 29, 30 &
31]. A large meta-analysis of major heart failure trials has shown that the prevalence of anemia
was around 37% in all patients with heart failure [32]. Approximately 20% of patients with colon
cancer experience gastrointestinal bleeding, eventually leading to cause iron deficiency anemia
(IDA) [33]. A recent study by Gupta et al showed that iron deficiency anemia might be a factor
for the co-morbidity of migraine and restless leg syndrome [34]. Iron deficiency anemia is also
common in patients with menstrual migraine [35].
1.5. Iron for therapeutic purposes
The use of iron for therapeutic purposes has been in practice from ancient times. Ancient
Greeks used iron salts in the diet to treat muscular weakness in wounded warriors [36]. Nicholas
Monarde, a 16th century physician used iron for a large number of unrelated ailments including
gout, acne and alopecia [37]. In the second half of the seventeenth century, Thomas Sydenham,
suggested iron as a treatment option for chlorosis in young woman, which they used to refer as a
“hysterical disease” or Virgin’s disease [38].
1.6. Treatment Options for Iron deficiency anemia
Hydrophilic oral iron salts or colloidal parenteral iron complexes are the treatment
options for body iron replenishment since several decades. The existing treatment with oral and
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parenteral iron formulations is associated with severe side effects along with various other
patient noncompliance issues.
1.7. Oral iron therapy
Oral iron formulations are the choice of first line therapy to replenish body iron stores.
Oral iron salts that are widely used in clinical practice are listed in table 1. All iron salts differ in
their elemental iron content and the usual treatment regimen with oral iron salts ranges from
three to six months.
Formulation
Carbonyl Iron(U.S Only)
Ferric Ammonium citrate
Ferrous bisglycinate
(U.S Only)
Ferrous fumarate
Ferrous gluconate
Ferrous sulfate
Ferrous sulfate, dried
Heme-iron polypeptide
Polysaccharide-iron
complex

%Elemental
Iron(w/w)
100
18
20
33
12
20
30
100
100

Table 1-1.List of oral iron preparations available for clinical use along with their elemental iron
content.
Iron is absorbed mostly from the proximal part of the small intestine and only a fraction
of the total oral dose is bioavailable due to the carrier mediated absorption mechanism.
Moreover, bioavailability of iron from oral administration is regulated by the total iron stores in
the body [39]. Until most of the iron stores are exhausted, iron absorption from gut is not
increased. Although oral iron therapy is convenient, gastric intolerance and poor adherence of
the oral therapy due to unpleasant taste and odor of iron salts are the common disadvantages
associated with it [40]. An increase in the dose of oral iron in an effort to increase absorption will
6

only result in increased gastrointestinal toxicity.Moreover, oral iron supplements have limitations
in IDA treatment in case of chronic intestinal bleeding, hemodialysis, malabsorption syndrome,
Crohn’s disease, inflammatory bowel disease, and chronic bowel obstruction. The most common
side effects with iron salts include heartburn, nausea and vomiting, upper gastric discomfort,
diarrhea, and constipation. Gastrointestinal symptoms related to oral iron therapy range in
frequency from 15% to 40% depending on dose and other factors [41, 42].
Oral iron salts are generally ineffective in the immediate post-surgical settings due to
post-surgical inflammation in the gastrointestinal system.Oral salts should be preferably taken on
an empty stomach or between meals to facilitate absorption, butepigastric pain is a common
complaint among patients if iron is administered in the fasted state. For such patients, it was
advised to take oral iron salts along with the meal, but absorption get dampens with food [43].
Oral iron absorption reducesby phytatesand other foods rich inpolyphenols which form large
insolublecomplexes with iron salts. Hepcidin, a hepatic peptide hormone play a huge role in
regulating the absorption of iron from the gastrointestinal tract and any hepcidin related disorders
have indirect effect on iron absorption from the intestine.
1.8. Parenteral iron therapy
Due to limitations and side effects associated with oral delivery, parenteral administration
of iron is often preferred or inevitable in some cases. Soluble iron salts used in oral therapy are
not suitable for parenteral delivery due to liberation of free ironwhich in turn leads to lipid
peroxidation and oxidative stress. A few heavy iron colloid complexes are in use for parenteral
delivery but they are not well tolerated among various patient groups. Parenteral iron
formulations that are approved for parenteral therapy are summarized here in table 1-2.
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Example

Type I
Type II
Ferric
Iron sucrose
carboxymaltose
Iron dextran
Ferumoxytol

Characteristics

Robust
Strong

Semi-robust
Moderately
strong

Molecular
weight(Daltons)

>100,000

30,000100,000

Type III
Type IV
Sodium ferric
Iron(III)gluconate
citrate+iron(III)Iron(III)-citrate
sorbitol+iron
Iron(III)dextrin
sorbitol
Sodium ferric
gluconate+iron
sucrose
Labile
Mixtures
Weak
containing at
least two
different iron
complexes
<50,000
<50,000

Table 1-2.List of parenteral iron formulations with molecular weights.
( ⃰ Modified from Geisseret al. Pharmaceutics 2011, 3, 12-33)
Usually, intravenous bolus iron injection is indicated in patients with intestinal
malabsorption and they are also considered to be superior to replenish large quantities of iron
where the ongoing iron losses exceed the absorptive capacity of oral iron. Intravenous bolus iron
therapy is also associated with significant side effects like hypotension, arthralgias, and severe
allergies and may cause anaphylactic reactions in case of iron overload [44]. Therefore,
intravenous infusions are preferred over frequent bolus injections. However, intravenous infusion
is invasive and associated with high treatment cost. Parenteral iron therapy is usually
recommended only in severe anemic conditions due to its invasiveness and systemic side effects
due to colloidal nature of the parenteral iron products Moreover, the iron overload with
parenteral formulations was reported to cause anaphylactic reactions and rarely even mortality
[45, 46]. The colloidal iron is processed by reticuloendothelial system (RES) to liberate iron
which binds to transferrin eventually and delivered to bone marrow for erythropoiesis [47, 48].
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CHAPTER 2
TRANSDERMAL DELIVERY OF IRON-APPLICATION OF PASSIVE AND ACTIVE
TECHNIQUES
2.1. INTRODUCTION
2.1.1. Skin and drug delivery pathways in the skin
Skin is the largest organ of the body and plays a vital role as a defense system to protect
the body from external assaults and prevents evaporation of moisture from the body to the
external environment [49]. Skin is composed of three main layers; epidermis, dermis and
hypodermis (subcutaneous adipose tissues) [figure 2-1]. Each layer in the skin is known to
represent different levels of cellular or epidermal differentiation and the barrier function of the
skin reflects through its multilayered structure.
The top or uppermost layer of the skin, known as the stratum corneum is the rate limiting
barrier for passive delivery of drugs [50]. The stratum corneum is comprised of dead cells
(corneocytes) dispersed within a lipid rich matrix. The closely packed keratinocytes as well as
the intercellular lipid bilayers in the stratum corneum offer resistance for permeation of polar
drugs. Moderately lipophilic drugs are relatively more permeable than extremely hydrophilic and
extremely lipophilic molecules. Moreover, the molecular weight of the drugs should be <500 Da
to be permeable across the skin. When the drug possesses all these properties, it would be ideal
for transdermal delivery provided the dose required is not impractical. In general, drug molecules
that are in contact with the skin surface can penetrate by three potential pathways: through the
lipids in the stratum corneum (intercellular pathway), through both the lipids and the
9

keratinocytes-directly across stratum corneum (transcellular pathway), through the sweat ducts,
via the hair follicles and sebaceous glands (The shunt or transappendageal route) [51].

Figure 2-1. Transverse section showing different layers of skin and the major drug
transportpathways via skin.
2.1.2 Need for transdermal iron delivery
Delivering therapeutically adequate amounts of iron to treat iron deficiency anemia
(IDA) still remains a challenge due to the adverse effects associated with oral and parenteral iron
preparations especially in children and pregnant women. Therefore, there is an indispensable
need for the development of an alternative and safe mode of administration of iron products.
Transdermal delivery of iron could be a potential method of treating iron deficiency due to safety
and patient compliance that this route could offer. Transdermal delivery of iron would be
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attractive to patients due to the fact that transdermal route could overcome the potential gastric
and systemic side effects associated with oral and parenteral formulations respectively. The
plausibility of slow and controlled delivery of iron across the skin is possible with transdermal
delivery. Slow and prolonged delivery of iron has been reported to be relatively safer than rapid
infusion and bolus injections of iron as the former would reduce the likeliness of oversaturation
of transferrin [52, 53]. Transdermal delivery allows administration of drugs over long durations
simulating slow intravenous infusion. In case of transdermal iron delivery, the choice of iron
salts is challenging because all the iron salts used in oral iron therapy are hydrophilic in nature
and the products approved for parenteral therapy are huge in size due to their colloidal nature.
Not all iron salts could be administered parenterally and, not suitable to transdermal delivery, as
there is risk of potential oxidative stress due to free radical formation.
2.1.3 Ferric Pyrophosphate
Therefore, to develop a successful transdermal therapeutic system of iron, there is a need
to identify low molecular weight iron compounds, which are safe. In a recent study by Gupta et
al,Ferric pyrophosphate (FPP) demonstrated superior safety in maintenance hemodialysis
patients without any evidence of toxicity and proved to support erythropoiesis and maintain
hemoglobin levels [54]. FPP is a combination of ferric form of iron and pyrophosphate salt and
has a high stability constant (log Kstab 22.3).Due to this high stability,FPP does not dissociate and
liberate free iron in the physiological fluids unlike other soluble salts [55]. Iron derived from FPP
was proved to taken up directly and rapidly by circulating apo-transferrin within minutes of
exposure [56]. Moreover, FPP can trigger the direct transfer of iron between transferrin and
ferritin and transferrin [55, 57]. In addition, pyrophosphate was also proved to be a potent
antioxidant [58]. From all these scientific evidences from Gupta et al. and others, FPP was
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thought to be a suitable candidate for transdermal delivery for iron replenishment therapy. In the
current project, the possibility of delivering soluble FPP via transdermal route was explored
using various passive and active techniques.

Figure 2-2. Structure of Ferric Pyrophosphate

2.2. MATERIALS AND METHODS
2.2.1. Chemicals
Soluble Ferric pyrophosphate was obtained from Sigma-Aldrich Inc (St. Louis, MO).
Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained from EMD Chemicals
(Gibbstown, NJ). Ferrover® iron was purchased from Hach Company (Loveland, OH). All other
chemicals and solvents used were of pure grade obtained from Fischer scientific (Fairway, NJ).
2.2.2. Preparation of rat skin/porcine epidermis
FPP permeation studies were carried out using both rat skin and porcine epidermis. For
the preparation of rat skin, the animals [Male hairless rats (Charles River, Wilmington, MA,
USA)] were asphyxiated with CO2 and the abdominal skin was excised, subcutaneous fat was
removed and the obtained skin pieces were cleaned carefully with normal saline. The rat skin
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was used either on the same day or stored at -20 °Cfor further use. The animal studies were
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
Mississippi (Protocol # 10-013). Porcine full thickness skin was obtained from a local abattoir
and epidermis was peeled off from full thickness skin after heat treatment at 60 °C for 2 minutes.
2.2.3.General experimental set up
Vertical Franz diffusion cell (PermeGear Inc., Hellertown, PA) set up was used to
investigate the permeation of FPP across rat skin or porcine epidermis. The tissue (either rat skin
or porcine epidermis) was sandwiched between the donor and receiver compartment of Franz
diffusion cell in such a way that dermal side of tissue was in contact with receiver compartment
and stratum corneum was facing the donor compartment of the cell. The active diffusion area
was 0.64 cm2. Electrical resistance across the tissue was used to check the integrity of the barrier.
For this set up, Ag/Agcl wires (Alfa-Aesar, Ward hill, MA) made in the form of circular rings
and arranged at a distance of 2 mm from the tissue in both donor and receiver compartment. The
donor and receiver compartments were filled with 0.5 ml and 5 ml of PBS having a pH of 7.4
and allowed to equilibrate for one hour. The AC electrical resistance of the skin (Rs) was
measured by placing a load resistor RL (100 kΩ) in series with the tissue as reported previously
[59]. The voltage drop across the whole circuit (V0) and across the skin (Vs) was measured using
an electrical set up consisting of a wave form generator and a digital multimeter (Agilent
Technologies, Santa Clara, CA). Skin resistance was measured by applying a voltage of 100 mV
at 10 Hz in the electric setup. Tissues maintaining a resistance of ≥20 kΩ/cm2 wereonly
considered for permeation studies.
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2.2.4. In vitro permeation studies
2.2.4.1. Passive permeation
After measuring electrical resistance of the tissue, the PBS in the donor compartment of
the Franz diffusion cell was replaced with 0.5 ml of FPP aqueous solution (50 mg/ml, pH-5) and
receiver compartment was filled with 5 ml of PBS adjusted to pH-5 using 1 N hydrochloric acid.
During in vitro permeation studies, the temperature of receiver compartment was maintained at
37±1°C by water circulation. Permeation studies were carried out for 6 hourswhen rat skin was
used and all porcine epidermis permeation studies were carried out for 24 hours. One ml of
sample was withdrawn from receiver compartment at every hour time point and replaced with
fresh buffer solution. The amount of FPP permeated was analyzed using Ferrover® iron reagent,
using Lambda EZ201 UV spectrophotometer (Perkin Elmer, Waltham, MA) at 510 nm.
2.2.4.2. Passive permeation studies across porcine epidermis using chemical permeation
enhancers
Various transdermal chemical permeation enhancers (CPEs) belongs to different
chemical classification such as sulfoxides, fatty acids, fatty acid esters, amides and surfactants
were selectedin order to study the effect of enhancerson permeation of FPP, in vitro.The
following chemical permeation enhancers at given concentrations were used for the study; 10 %
v/v dimethyl sulfoxide,

1% w/v N-vinyl 2- pyrrolidone, 10 % v/v Transcutol, 20 %

v/vTranscutol, 20 % v/v polyethylene glycol (PEG) 400, 20% v/v- Tween 80, 20% v/v Tween
20, 10% w/v urea, 20 % v/v (SLS), cetyltrimethylammonium bromide(CTAB) 20%v/v, 10%
v/visopropyl myristate (IPM) and 20% w/v sodium laurylsulfate (SLS).

In few other

experiments the following combination of enhancers was also used; Transcutol 25 %v/v +
propylene glycol 25 % v/v, Transcutol10%v/v + propylene glycol 40% v/v. The effect of
pretreatment with some chemical permeation enhancers on the permeation FPP was also
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investigated. Pretreatment was carried out for 30 minutes and the following enhancers were
selected for the study; 1-phenyl piperazine (ashort chain azone), 10 % v/v oleic acid in propylene
glycol, 10 % v/v oleic acid, 5 % v/v linoleic acid.

After pretreatment with enhancer or

combination of enhancers, 0.5 ml of FPP (50 mg/ml) was loaded into the donor chamber and
permeation studies were carried out for 24 hours. Samples were withdrawnat regular intervals of
time for a period of 24 h from thereceiver compartment and the iron content was measuredat 510
nm by adding Ferrover® iron reagent usingUV spectrophotometer.
2.2.4.3. Iontophoretic delivery
Cathodaliontophoresis was carried out using Phoresor®iontophoresis unit (Iomed, Salt
Lake City, UT) at 0.3 mA/cm2 for 6 hoursacross rat skin. When porcine epidermis was used,
cathodaliontophoresis was carried out using Phoresor®iontophoresis unit at 0.3 mA/cm2for 24
hours. The electrodes made up of Ag/AgCl were connected with the lead clips from Phoresor®
Unit. Donor chamber was filled with 0.5 ml of FPP aqueous solution and receiver with PBS
adjusted to pH-5 using 1 N hydrochloric acid. One ml samples were collected at each hour
interval and analyzed for FPP.
2.2.4.4. Passive permeation studies across porcine epidermis using chemical permeation
enhancers+ iontophoresis
Few selected permeation enhancers that resulted in positive enhancement of FPP in
earlier studies were used along with iontophoresis to investigate the effect of combining both the
approaches. Cathodaliontophoresis was applied using Phoresor® iontophoresis unit at 0.3
mA/cm2 for 24 hours. The electrodes made up of Ag/AgCl were connected with the lead clips
from Phoresor® unit. Donor chamber was filled with 0.5 ml of FPP aqueous solution containing
enhancerand receiver with PBS adjusted to pH-5 using 1 N hydrochloric acid. One ml samples
were collected at each hour interval and analyzed for FPP.
15

2.2.4.5. Permeation studies after pretreatment with microneedles across rat skin
The rat skin was pretreated with microneedles[AdminPen 600 stainless steel
microneedles(nanoBioScience LLC.Alameda, CA)]for 2 minutes. The microporated skin was
mounted carefully on Franz diffusion cell and continued with either passive permeation studies
or iontophoretic mediated delivery (0.3 mA/cm2) as described in passive permeation and
iontophoretic delivery sections respectively. Microneedles were inserted into the skin with the
thumb, each time with uniform force by same individual to avoid variability in the depth of skin
penetration.
2.3. RESULTS & DISCUSSION
2.3.1. Passive delivery of Iron compounds across skin
Passive delivery of FPP was not successful due to poor permeation properties of FPP
because of its high molecular weight (~745 Da) and low lipid solubility. The amount of FPP
delivered across rat skin after 6 hours was only 6.53 ± 0.45μg/cm2. Even after 24 hours, the
amount of FPP delivered across porcine epidermis was only 16.6 ± 3.16 μg/cm2.
2.3.2. Chemical permeation enhancers
For successful delivery of FPP, the effect of chemical permeation enhancers was
evaluated in this study. Chemical permeation enhancers act inmany different ways; by increasing
drug solubilityor by disrupting the lipid bilayers in the stratum corneum or by enhancing
partitioning of drugs in different layers of the skin and by keratin denaturation [60-63]. Among
the permeation enhancers tested, only 10 % v/v DMSO, 10 % w/v urea and 20 %w/v SLS
resulted in significant improvement in passive delivery of FPP compared to the control. DMSO
at 10 % v/v concentration enhanced the total amount of FPP permeated by ~3 folds compared to
passive permeation and there was ~2.5 fold enhancement in permeation with 10 % w/v urea and
~ 3 fold enhancements in permeation with 20 % w/v SLS.
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DMSO was reported to be effective transdermal enhancer and acts by enhancing the
diffusion coefficient of drugs by disrupting the lipid bilayer and partitioning of the drug in the
skin [64, 65]. Urea might be promoting transdermal permeation by facilitating hydration of the
stratum corneum and by the formation of hydrophilic diffusion channels within the stratum
corneum barrier by disruption of the lipid packing [66,67]. SLS is an anionic surfactant and it
was proved toincrease the drug permeation across skin by disrupting the lipid bilayers and by
increasing the partition of drug in various layers. SLS was proved to increase the in vitro
permeation rates of several drugs including naproxen[68] and naloxone [69]. Non-ionic
surfactants like Tween 20 and Tween 80 are ineffective for permeation enhancement of FPP. The
results of transdermal permeation of FPP with all chemical permeation enhancers and

Amount of FPP permeated in
24 hrs (µg/cm2)

combinations of enhancers are shown in figure 2-3.
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Passive, DMSO (10 %w/v), PEG 400 (20 % v/v), Urea (10%w/v), SLS (20% w/v)tween 80 (20% v/v), Tween 20 (20%
v/v), Transcutol (10 %v/v and 20 % v/v), CTAB (10 % v/v), N-vinul-pyrrolidione (1% w/v), IPM (10%v/v), Trancutol
(25% v/v)+ Propylene glycol, Trancutol (10% v/v)+ Propylene glycol.
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Figure 2-3. The cumulative amount of FPP permeated across porcine epidermis in presence
of various chemical permeation enhancers. The data points represented are the average of n=
6 ± S.D.
In case of skin pretreatment with chemical permeation enhancers, 10 % oleic acid in
propylene glycol resulted in ~2 fold enhancement in the total amount of FPP permeated across
porcine epidermis in 24 hours. The other enhancers were not effective and the results are shown

Amount of FPP permeated
in 24 hrs (µg/cm2)

in figure 2-4.
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Figure 2-4. The cumulative amount of FPP permeated across porcine epidermis after
pretreatment with various chemical permeation enhancers. The data points represented are the
average of n= 6 ± S.D.
Oleic acid enhancing activity was found to be dependent onthe use of a co-solvent, such
as propylene glycol, whichusually acted synergistically [70,71]. Oleic acid is a monounsaturated
fatty acid,exists as heterogeneously dispersed fluid domain in the stratum corneum and enhances
the permeation of active by improving diffusion and partition of the drug by fluidization of
stratum corneum lipids [72].
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2.3.3. Iontophoresis
Iontophoresis is a safe and effectivetechnique to enhance the delivery of drugs across the
skin. Iontophoresis utilizes low density electric current and enhances transdermal drug transport
via direct electrophoresis, electroosmosis, or by lipid bilayer disordering[73, 74]. The
appendageal pathway is the predominant pathway forenhancementof drug delivery by
iontophoresis. Iontophoresis can provide programmable delivery of drug across the skin by
altering current strength or duration [75].
The in vitro flux of FPP withiontophoresis (IN) applicationafter 6 hours was 8.04 ± 0.24
μg/cm2/h which was ~8 fold enhancement compared to the passive flux of FPP across the rat
skin. In another study with the use of porcine epidermis there was a ~10 fold enhancement in the
permeation flux of FPP with iontophoresis compared to passive delivery. Transdermal
iontophoresiswas proved to be a useful technique to enhance the delivery of FPP for the
treatment of anemia.
2.3.4. Permeation enhancers + Iontophoretic delivery
Combination of several penetration enhancerswith iontophoresis has been reported by
several authors in the past[76-78].Greater amounts of drug could be delivered when permeation
enhancers were combined with iontophoresis thaneither technique alone. In the present study, the
chemical permeation enhancers that were proved to be effective in enhancing the passive FPP
delivery were chosen for iontophoretic delivery of FPP. The results are shown in figure 2-5.
When DMSO combined with iontophoresis there was a slight improvement in the amount of FPP
delivered, which was not significant compared with iontophoresis alone. In case of iontophoresis
+ urea (10 % w/v) and iontophoresis + SLS (20 % w/v) combinations, there was no significant
difference between the amount of FPP delivered when compared with iontophoresis alone.
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Figure 2-5. The cumulative amount of FPP permeated across rat skin with various chemical
permeation enhancers along with iontophoresis(IN) (0.3 mA/cm2). The data points represented
are the average of n= 6 ± S.D.
2.3.5. Microneedle pretreatment (MN)
Rat skin was pretreated with solid microneedles for 2 minutes and FPP delivery studies
were carried out for 6 hours. The in vitro flux of FPP after microneedle (MN) pretreatment was
12.36 ± 0.16 μg/cm2/h which was ~11 fold compared to the passive flux of FPP.
From the above results, it was confirmed that creation of micropores in the skin can
improve permeation of FPP across skin. However, microneedle pretreatment alone did not lead
to a significant increase (to meet therapeutic requirements in severe anemic cases) in the iron
delivery which is likely because of the closing of micropores by physical barrier(property of
skin) over a period of time. Here, to make the best use of micropores formed withmicroneedle
pretreatment, two approaches were followed.
Approach I. Transport FPP through micropores created due to microneedle pretreatment.
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Approach II. Deliver FPP using soluble microneedles which stay in the pores over prolonged
duration without allowing them to close rapidly.
For this purpose, we initially tried approach 1 by combining the iontophoresis(driving
force)along with microneedle pretreatment to drive FPP across microporated skin.
2.3.6. Microneedle pretreatment (MN) + Iontophoresis (IN)
In case of the combination of microneedle pretreatment along with cathodaliontophoresis
(MN+IN), there was ~44 fold enhancement in the flux (51.24 ± 7.55 μg/cm2/h) over passive
permeation in 6 hours.

In a separate set of studies, in vitro permeation studies of FPP

fromhydroxyl propyl methyl cellulose(HPMC) gel across rat skin were performed with MN+IN
treatment and the resulting flux was almost the same (~50.45 ± 5.62 μg/cm2/h) as with FPP
solution.Successful transdermal delivery ofcertain hydrophilic compounds and high molecular
weight peptide drugs using combination of microneedle pretreatment with iontophoresis has
been demonstrated by various groups in the past [79,80].
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Figure2-6.The cumulative amount of FPP permeated across rat skin in case of passive (♦),
iontophoresis (IN) (■), microneedle pretreatment (MN) (▲) and combination of microneedle
pretreatment with iontophoresis (MN+IN) (●).Permeation studies were carried out for 6 hours.
The data points represented are the average of n= 6 ± S.D.
2.4. SUMMARY
From all the in vitro permeation experiments of FPP, when iontophoresis applied across
porcine epidermis there was ~10 folds enhancement in the permeation flux after 24 hours
compared to passive delivery. Among all the permeation enhancers tested only 10 % v/v DMSO,
10 % w/v urea and 20 %w/v SLS showed significant improvement in the permeation compared
to passive delivery. When these enhancers combined with iontophoresis there was no significant
improvement in the permeation compared to iontophoretic delivery alone. The Passive flux of
FPP across hairless rat skin after 6 hours was 1.16 ± 0.16 μg/cm2/h. After IN treatment alone
there was ~8 folds enhancement in permeation flux compared to passive delivery and after
microneedle (MN) pretreatment alone there was ~11 folds enhancement compared to passive
flux. Whereas, when iontophoresis was combined with microneedle pretreatment there was ~ 44
folds enhancement in the flux compared with passive permeation and iontophoreis in
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combination with microneedle pretreatment was proved to be the most effective technique for
transdermal delivery of iron.
2.5. CONCLUSIONS
The results of the study suggest that FPP can be delivered via transdermal route using
passive (permeation enhancers) and active techniques (iontophoresis, microneedle pretreatment
and iontophoresis in combination with microneedle pretreatment). Even though, the amount of
iron delivered was low using chemical permeation enhancers,withiontophoresis alone and with
microneedle pretreatment alone; these techniques can find applications in transdermal delivery of
iron to treat mild to moderate anemia in patient who cannot tolerate oral iron formulations
(especially pregnant women and children).Moreover, these techniques will be of great advantage
in terms of non-invasiveness and safety compared to parenteral iron formulations. Successful
development of transdermal iron delivery system with the above enhancement techniques will be
very useful in patients who are on maintenance therapy for iron deficiency anemia.
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CHAPTER 3
MICROPORATION AND ‘IRON’TOPHORESIS FOR TREATING IRON DEFICIENCY
ANEMIA IN ANEMIC RAT MODEL

ABSTRACT
Purpose:Iontophoretic mediated transdermal delivery of ferric pyrophosphate (FPP) in
combination with microneedle pretreatment was investigated as a potential treatment option for
iron deficiency anemia (IDA).
Methods:In vivo pharmacodynamics studies were performed in hairless anemic rat model. The
hematological and biochemical parameters like hemoglobin, hematocrit, mean corpuscular
volume and % serum transferrin were monitored in rats at healthy, anemic condition and post
treatment conditions. Micropores created by the microneedles were visualized inhistological skin
sections after staining them with hemotoxylin and eosin. The recovery of micropores was
investigated in vivo by measuring Transepidermal water loss (TEWL) at different time points.
Results: The passive, microneedlepretreatment and iontophoresis mediated delivery did not lead
to significant improvement in hematological and biochemical parameters in anemic rats, when
used individually. When iontophoresis (0.15 mA/cm2 for 4 hours) was combined with
microneedle pretreatment (for 2 minutes), therapeutically adequate amount of FPP was delivered
and there was significant recovery in hematological and biochemical parameters in rats
indicating this treatment will be effective in treating IDA.
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Conclusions:Microneedles pretreatment and iontophoresis mediated delivery of iron via
transdermal route could be developed as a potential treatment for IDA. The transdermal
controlled delivery of iron could become a potential, safe and effective alternative to parenteral
iron therapy.
3.1. INTRODUCTION
Transdermal delivery of iron to treat iron deficiency anemia in anemic animal models
was investigated. From our earlier in vitro studies, it was evident that ionotophoresis,
microneedle pretreatment alone and combination of microneedle pretreatment andiontophoresis
were able to deliver significant amount of FPP across the skin. In the present study, our aim was
to investigate the delivery of iron across skin in anemic animal models using these active
techniques to treat iron deficiency anemia. In vivopharmacodynamic studies were carried out to
measure various hematologic and biochemical parameters in rats at healthy, anemic and treated
conditions. Red blood cell morphology studies were also carried out to show the efficacy of the
treatments.
3.2. MATERIALS AND METHODS
3.2.1. Chemicals
Soluble Ferric pyrophosphate was obtained from Sigma-Aldrich Inc (St. Louis, MO).
Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained from EMD Chemicals
(Gibbstown, NJ). Hydroxypropyl methyl cellulose (Methocel® E15 premium LV) was obtained
from Dow chemical company (Midland, MI). Ferrover® iron was purchased from HachChemical
Company (Loveland, OH). Serum iron & TIBC kit was procured from Cliniqa Corporation (San
Marcos, CA). Lipid peroxidation assay kit (OXI-TEK TBARS assay) was obtained from Enzo
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Life Sciences (Farmingdale, NY). All other chemicals and solvents used were of pure grade
obtained from Fischer scientific (Fairway, NJ).
3.2.2. Experimental animals and preparation of skin
Male hairless rats (Charles River, Wilmington, MA, USA) were used forin vivo studies.
All the animal studies were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Mississippi (Protocol # 10-013). All the animals were of eight
weeks old and weighing between 250-300 g at the time of arrival. The animals were housed in
conventional cages and 12 hour day/light cycles were maintained in the facility.
3.2.3. Preparation of hydroxypropyl methyl cellulose (HPMC) gel incorporated with FPP
FPP solution was prepared by dissolving 50 mg of soluble FPP in 1 ml of distilled water
and pH was adjusted to 5 using 1 N hydrochloric acid (HCl). HPMC (4% w/v) gel was prepared
according to the standard protocol given by the polymer manufacturer; briefly by mixing the hot
polymeric aqueous solution to the cold solution of FPP to give a final concentration of 50 mg/ml
of FPP in the gel.
3.2.4. Microneedles
AdminPen 600 stainless steel microneedles(nanoBioScience LLC.Alameda, CA) having
an area of 1cm2and containing 187 microneedles with a needle height of 500 µm were used in all
ex vivo and in vivo studies.
3.2.5. Visualization of micropores
The depth of penetration of microneedles was visualized by staining the histological
section of the microneedle pretreated skin with hematoxylin and eosin. Briefly, freshly excised
skin was microporated with the microneedles for 2 minutes. Small skin samples with micropores
were fixed in optimum cutting temperature (OCT) medium (Tissue-Tek®) and frozen in dry ice
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bath and sectioned at 50 µm on a Leica 1800 cryostat. The obtained skin specimens were stained
with hematoxylin and eosin and observed under high resolution light microscope (Axiolab, A1,
Carl Zeiss, USA) at 10X magnification to visualize depth of penetration of microneedles into
different layers of skin. Images were captured using a Carl Zeiss camera attached to the
microscope.
3.2.6. In vivo studies
In vivo experimental studies were carried out in hairless rats. The rats were acclimated to
vivarium conditions for one week with regular standard diet. Blood samples were drawn from all
animals by retro-orbital bleeding and analyzed for hematological and biochemical parameters.
Initially 200 µl of blood samples were collected in EDTA (ethylenediaminetetraacetic acid)
coated Microvette® tubes (Sarstedt, Newton, NC) and 0.5 ml of blood was collected into 1.5 ml
centrifuge tubes (Eppendorf, Hauppauge, NY) from all animals. The blood sample collected into
EDTA tubes were analyzed for the hematologic parameters like hemoglobin (Hb), red blood cell
(RBC) count, hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell distribution
width (RDWc) using VetScan HM2 hematology system (Abaxis Inc., Union city, CA) (figure 31).
Serum was separated from the blood samples collected into centrifuge tubes after
centrifugation at 3000 rpm for 10 minutes and analyzed for biochemical parameters. The serum
iron, total iron binding capacity of serum and % transferrin saturation (%TS) was calculated
using serum iron & TIBC kit (Cliniqa Corporation, San Marcos, CA). Serum lipid peroxidation
values were calculated using OXI-TEK TBARS assay kit (Enzo Life Sciences Inc., Farmingdale,
NY). The base line values for all of these parameters in the healthy animals were recorded.
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Figure 3-1. VetScan HM2 Hematology system (Curtsey: Abaxis Inc., Union city, CA)
3.2.6.1. Induction of iron deficiency anemia
Rats were fed custom made purified low iron diet having iron concentration as low as 2-6
ppm (Harlan laboratories, Madison, WI) till the end of study period. The composition of the diet
was in accordance with AIN-76A guidelines with all vitamin and mineral mix except cellulose
and iron in it. Rats were allowed free access to this diet and water all the time. The degree of iron
deficiency was monitored by measuring the hematologic parameters (hemoglobin and
hematocrit) from collected blood samples every week, for 5 weeks. Induction of iron deficiency
anemia was confirmed after five weeks by measuring all hematologic parameters and
biochemical parameters.
3.2.6.2. In vivo delivery of FPP
FPP treatment was initiated, after confirming that the rats were anemic. Rats were
divided randomly into the following 6 groups (n=6) and FPP was administered to animals in
different groups as described below. All the in vivo transdermal studies were carried out on
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alternative days for 4 hours under ketamine (80 mg/kg) and xylazine (10mg/kg) anesthesia
administered intraperitoneally. Transdermal patch having an area of 10 cm2 was applied in all the
groups except group 6 as specified below. FPP was administered transdermally for 4 weeks in
groups 2, 3, 4 & 5. Group 6 animals were administered with FPP intraperitoneally.
Group 1: Placebo group
A placebo patch (HPMC gel patch with no FPP incorporated) was placed on the rats for 4
hours.
Group 2: FPP-Passive group
In case of passive delivery, a patch containing FPP-HPMC gel (500 mg) was applied on
the back of rat. No current was applied and the FPP was allowed to permeate passively.
Group 3: Iontophoresis group (IN)
For iontophoretic delivery, a custom made iontophoretic patch was prepared using an
adhesive 3M™ foam tape (3M Drug Delivery Systems, St. Paul, MN) fitted with a snap type
Ag/Agcl electrode. FPP-HPMC gel was loaded on to the patch and secured on the back of the
rat’s body and cathodaliontophoresis was applied at a current strength of 0.15 mA/cm2.
Group 4: Microneedle group (MN)
Rats were pretreated with microneedles for 2 minutes using 1 cm2 array over a total area
of 10 cm2. Precautions were taken to avoid overlapping of microporation by marking the already
pretreated areas. FPP gel patch was applied immediately after pretreatment and permeation
studies were carried out.
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Group 5: Microneedle + iontophoresis (MN+IN) group
In the MN + IN group, rats were pretreated with microneedles for 2 minutes and
cathodaliontophoresis was applied as described above after applying a custom made
iontophoretic patch.
Group 6: Intraperitoneal (IP) group
FPP was dissolved in normal saline to get a concentration of 10 mg/ml. Rats were
administered with 0.11 ml of this solution via intraperitoneal route for 3 weeks. This group
served a positive control for the study.
Blood samples were withdrawn intermittently and at the end of study period from all
animals by retro orbital bleeding and all hematology and biochemical parameters were analyzed.
3.2.7. Recovery of micropores
In a different set of experiment, the TEWL was measured using Vapometer (Delfin
Technologies, Kuopio, Finland) in vivo on hairless rat skin after pretreatment with microneedles
to study the effect of microneedles on skin and the recovery of barrier property. The TEWL of
rat skin before and after pretreatment with microneedles was measured at different time points.
3.2.8. Red blood cell Morphology
Visualization of RBC under high resolution microscopy was performed to study the
morphology of RBC at healthy, anemic and treated conditions in animals from all groups.
Briefly, peripheral blood smear was prepared by wedge slide method using a drop of venous
blood collected from animals at healthy, anemic and treated conditions. The dried smears were
stained with Wright-Giemsa stain and the red blood cells were visualized under high resolution
light microscope (Axiolab A1, Carl Zeiss, USA) at 100x magnification using oil immersion
technique. Images were captured using Carl Zeiss camera attached to the microscope.
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3.2.9. Statistical analysis
GraphPadInStat 3 software was used for statistical analysis. Unpaired t-test was used to
determine the level of significance for correlations between parameters at healthy and anemic
conditions and between anemic condition and post treatment condition in all groups. A
significance level of p< 0.05 was considered as statistically significant.
3.2. RESULTS& DISCUSSION
From the previous studies,the transdermal delivery of FPP by iontophoresis could be
significantly enhanced when the stratum corneum barrier is compromised. Based on earlier
observations, the present study was planned to investigate the effect of microporation on the
passive and iontophoretic delivery of FPP across the skin. Both iontophoresis and microneedle
treatment are active transdermal drug delivery techniques that enable drugs to permeate across
the skin. Iontophoresis utilizes low density electric current to drive charged drugs across the skin.
Microneedles create micropores in the startumcorneum of the skin and allow drugs to permeate
into deeper layers [81]. The microneedles used in this study were able to penetrate down to an
average depth of 70 ± 10 μminto the skin. The micropores created by microneedles were
visualized in the skin sections stained with hematoxylin and eosin which are shown in figure 3-2.
The picture clearly indicated that the microneedles penetrated only through the upper layers of
the epidermis.
From in vitro investigations, when microneedle pretreatment was combined with
cathodaliontophoresis (MN+IN), there was ~44 fold enhancement in the permeation flux
compared to passive permeation. At this flux, a cumulative dose of ~0.3 mg of FPP would be
delivered in six hours. Therefore, in case of in vivo studies, cathodaliontophoresis was applied
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using a current strength of 0.15 mA/cm2 for 4 hours after pretreatment with microneedles on
alternative days to deliver the required dose of FPP (1.1 mg of FPP ≈ 0.12 mg of elemental iron).

Figure 3-2.Histological section of skin treated with microneedles and stained with hematoxylin
and eosin stain shown at 10x magnification. The epidermis and dermal layers were shown clearly
in this picture.
3.3.1. In vivo studies
3.3.1.1. Recovery of micropores
The duration for the recovery of micropores created with microneedles was investigated
by measuring transepidermal water loss (TEWL). Immediately following pretreatment with
microneedles, there was an increase in TEWL observed from 13.6 ± 1.42 g/m2.h to 28.75 ± 2.68
g/m2.h owing to micropore formation.The TEWL values returned to normal (14.1 ± 2.22 g/m2.h)
within 8-12 hours (figure 3-3). This study suggests that the skin barrier remains compromised
forat least 8 hours even in un-occluded condition. On the other hand, the recovery of skin barrier
is almost complete within 8-12 hours after removal of the patch/device. From literature, few
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earlier studies have clearly shown that the pores reseal relatively faster in case of non-occluded
condition than when occluded [82, 83].
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Figure 3-3.The In vivo TEWL measurements after microporation at different time points. The
unfilled bar ( ) represents the TEWL of intact skin before microporation. The data points
represented are the average of n= 6 ± S.D.
3.3.1.2. Induction of anemia and diagnosis
Various conventional laboratory tests are available for successful diagnosis of iron
deficiency anemia. In the present work, hematologic and biochemical parameters were assessed
to confirm the induction of anemia and recovery from anemia following transdermal FPP
administration. The custom made purified low iron diet contains only trace quantities of iron (~ 4
ppm). After 5 weeks on this diet, there was a significant difference in the hematological
parameters in rats compared to basal healthy values indicating induction of anemia. There was
decrease in hemoglobin concentration and MCV along with other red blood indices. The serum
iron and % transferrin saturation were also decreased, whereas the TIBC values were increased
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in anemic condition. The observed hematological parameters and biochemical parameters in
healthy and anemic rats are shown in table 3-1.

Table 3-1: Observed mean hematological and biochemical parameters in rats at healthy state
(prior to iron free diet plan) and at anemic condition
Parameter

Basal values

Anemic condition

Hematological parameters
Hemoglobin (g/dl)

14.31 ± 2.47

10.58 ± 1.61†

HCT (%)

41.35 ± 8.33

32.4 ± 3.72†

MCV (fl)

56.25 ± 2.12

38 ± 2.86†††

MCH (pg)

19.56 ± 1.57

12.4 ± 1.22†††

MCHC (g/dl)

34.83 ± 1.61

28.22 ± 2.24††

RBC (1012/l)

8.40 ± 0.83

6.61 ± 0.75†

RDWc (%)

16.71 ± 2.22

28.33 ± 2.73†††

Serum Iron (µg/dl)

179.53 ± 15.84

83.46 ± 17.02†††

TIBC ((µg/dl)

374.86 ± 56.33

483.84 ± 57.91†

% TS

46.28 ± 7.04

16.59 ± 2.11††

8.58 ± 1.72

14.51 ± 3.92†

Biochemical parameters

Lipid peroxidation [equivalent to
MDA conc (nmol/ml)]

*The difference in all parameters in rats between healthy (basal values) and anemic conditions is
statistically significant.
†p<0.05
††p<0.001
†††p<0.0001
Measurement of hemoglobin concentration and hematocrit are considered to be most
appropriate indicators of IDA. Even the most common definitions of anemia by WHO and CDC
are based on the levels of hemoglobin present in the blood. The mean basal hemoglobin value of
the rats at healthy state was 14.31 ± 2.47 g/dl and decreased to 10.58 ± 1.61 g/dl (p = 0.01) at
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anemic condition and the mean % hematocrit value was decreased from 41.35 ± 8.33 % at
healthy state to 32.4 ± 3.72 % (p = 0.03) at anemic condition.A decrease in hemoglobin level
implies the decrease in amount of functional iron circulating in the blood. Hematocrit indicates
the proportion of whole blood occupied by the red blood cells and depends on the hemoglobin
concentration in red blood cells [84]. MCV is the average volume of a single red blood cell and it
serves as an important diagnostic tool in the differential diagnosis of anemia. Anemia is
classified as macrocytic (increased MCV), normocytic (normal MCV) or microcytic (decreased
MCV) on the basis of MCV. Iron deficiency is usually associated with microcytic anemia and
decrease in MCV value is one of the specific indicators for iron-deficiency anemia [84]. The
MCV values were also decreased after feeding rats with low iron diet and there was a difference
in mean MCV about 14.15 ± 0.74 fl from healthy to anemic state.
Red blood cells play a crucial role in the support of tissue metabolism and enough RBCs
must be available to maintain tissue oxygenation and sustain a normal acid-base balance in the
system [5].There was a reduction in mean RBC count from 8.4 ± 0.83 x 1012/l (healthy state) to
6.61 ± 0.75 x 1012/l (p = 0.002) (anemic condition). MCH and MCHC values indicate the
average amount and concentration of hemoglobin in red blood cells. MCHC is also an important
parameter that that indicates the cellular hydration status and the values usually decrease in IDA
(hypochromia). There was a 7.16 ± 0.35 pg difference in the mean MCH and 6.61 ± 0.6 g/dl in
the mean MCHC between healthy and anemic conditions in rats. The RDWc measures the
variation in red blood cell size and the mean values at healthy condition were 16.71 ± 2.22%,
which were increased to 28.33 ± 2.73 % at anemic condition (p< 0.0001), might be due to the
production of increased number of smaller RBCs (under developed) due to iron deficiency. The
increase in RDWc along with decrease in MCV is a precise diagnostic characteristic of iron
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deficiency anemia [85]. In this study a peripheral smear with microcytic and hypochromic
erythrocytes shown in figure 3-4b clearly confirms the presence of anemia in rats.
Among the biochemical parameters, the serum iron concentration values decreased from
179.53 ± 15.84 µg/dl to 83.46 ± 17.02 µg/dl (p<0.0001) and TIBC values increased from 374.86
± 56.33 µg/dl to 483.84 ± 57.91 µg/dl (p=0.008) after feeding the rats with custom made low
iron diet. Serum iron concentration is a measure of the total amount of iron in the serum bound to
transferrin. Transferrin is an iron transport protein, which carries iron to the bone marrow. Iron
readily bounds to unsaturated transferrin in the system. Measurement of serum iron
concentration alone might not be a useful indicator in the diagnosis of IDA because of its low
sensitivity. Moreover, many factors could affect the serum iron concentration such as a meal,
presence of infections or inflammations and existence of diurnal variations. TIBC measures the
total amount of iron needed to saturate serum transferrin. %TS is a ratio of serum iron
concentration and TIBC. TIBC and transferrin saturation (% TS) reflects the extent of vacant
iron-binding sites on transferrin. In the present experiment, the mean %TS value in rats at
healthy state was 46.28 ± 7.04, which were decreased to 16.59 ± 2.11 (p< 0.001) in anemic
condition.
Oxidative stress arises due to an imbalance between the formation and neutralization of
pro-oxidants which in turn leads to lipid peroxidation. Previously some researchers reported
higher lipid peroxide levels in anemic condition and, there are some conflicting reports as well
which showed lower or unchanged lipid peroxide levels in anemic condition [86-89]. In the
present study, the lipid peroxide level in anemic and treated animals were determined using an in
vitro diagnostic kit, which measures the increase in thiobarbituric acid reactive substances
(TBARS) which is an indicator of oxidative stress. In this test TBARS are expressed in terms of
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malondialdehyde (MDA) equivalents and the mean concentration of MDA in blood was 8.58 ±
1.72 nmol/ml at healthy condition. There was a significant increase (p=0.0068)

in MDA

concentration to 14.51 ± 3.92 nmol/ml at anemic condition, which agrees with reports that
explain the generation of lipid peroxides in case of IDA.
According to numerous scientific reports, various physiological mechanisms might be
responsible for the development of oxidative stress and lipid peroxidation in anemic animal
models [90-92]. The main reason for this observation was speculated to be due to accumulation
of free copper in liver cells or increase in the triglycerides concentration and increased fragility
of mitochondrial membranes [89, 93]. Balagopalakrishnaet al[94] and Nagababuet al[95]
demonstrated that the increase in oxidative stress of RBC might be due to decrease in the
oxygenation of hemoglobin and resultant increase in auto-oxidation of hemoglobin, which
further causes the generation of methemoglobin and superoxides.
3.3.1.3. Transdermal delivery of FPP in vivo
The anemic rats were segregated into different groups based on the mode of delivery and
the FPP was administered for four weeks. The hemoglobin and hematocrit were measured
intermittently during the treatment to assess the improvement in hematological parameters. There
was no significant improvement in the hematologic parameters in case of placebo group and
passive treatment groups (group 1 and 2 respectively). Rats in both of these groups had rather
turned more anemic likely because of negligible iron supplementation. Inevitably, the treatment
was terminated after two weeks in case of group 1 and 2. In vitro, cathodaliontophoresis and
microneedlesalone were found to enhance the delivery of FPP considerably. However, in vivo,
there was no significant improvement in hematologic parameters (Table 3-2) or morphology of
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RBC in iontophoresis alone and microneedle pretreatment alone groups (figure 3-4c, 3-4d), again
indicating that the amount of FPP delivered in these groups was sub-therapeutic dose.
The amount of iron required to restore the levels in IDA was calculated by different
investigators using different approaches based on the body weight and hemoglobin deficit.
Various mathematical relationships were derived based on the required hemoglobin to replenish
iron using oral and parenteral formulations [96, 5]. In the case of oral iron formulations the daily
required dose was calculated based on the amount of elemental iron present in these
formulations. According to CDC guidelines, for adults with anemia an oral iron dosage
containing 60 mg of elemental iron, one to two times a day is recommended assuming that at
least about 10 % will be absorbed from gastrointestinal system. For rats weighing ~250-300 gm,
an oral dose about 0.3 mg elemental iron per day is required.
In the current study, we targeted to deliver a cumulative amount of 0.12 mg of elemental
iron on alternate days (about ~ 60 µg on daily basis), using 10 cm2iontophoretic patch and a
current strength of 0.15 mA/cm2 for 4 hours transdermally. The FPP used in this study contains
~11.7 % elemental iron.The combination of microneedle pretreatment along with iontophoresis
resulted in significant improvement in the hematologic and biochemical parameters within four
weeks. There was an improvement in the mean hemoglobin concentration by ~2.5 g/dl from
anemic condition to post treatment. It has been reported that, a successful iron replenishment
therapy would result in improving hemoglobin concentration to 1-2 gm % in 2-3 weeks. Here, in
rats received iron via iontophoresis after microneedle pretreatment (group 5), the mean RBC
count increased from 6.61 ± 0.75 x1012/l (in anemic condition) to 7.72 ± 0.5 x 1012/l (p=0.013)
after treatment, indicating that the delivered iron was sufficient to meet the requirements for
regeneration of red blood cells. The mean hematocrit values also increased from 32.4 ± 3.72 %
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to 40.18 ± 4.24 % (p=0.0068) after treatment. Similarly, significant improvement in MCV,
MCH and MCHC were observed after four weeks of treatment in this group. A decrease in the
RDWc was also observed after treatment indicating a significant reduction in the abnormal size
and shaped RBCs owing to transdermal delivery of FPP in group 5 (Figure 3-4e).
The serum iron concentration and % TS and TIBC values in the treated rats in group 5
provided validity to the fact that adequate amount of iron was delivered when iontophoresis was
combined with microneedle pretreatment. The difference in lipid peroxidation after treatment
was not significantly different from that of anemic condition in the same rats, indicating that FPP
is not likely to increase the oxidative stress.
Table 3-2. The mean hematologic and biochemical parameters observed at the end of treatment
period in rats administered with FPP via different modes of administration.
Parameter

IN

MN

MN+IN*

IP

Hematological parameters
Hemoglobin (g/dl)

10.42 ± 1.11

10.55 ± 0.9

13.12 ± 0.6†

14.37 ± 0.41†

HCT (%)

34.62 ± 2.45

28.67 ± 1.52

40.18 ± 4.24†

42.0 ± 1.30††

MCV (fl)

39.2 ± 1.93

40.2 ± 1.4

46.45 ± 4.39†

46 ± 1.73††

MCH (pg)

11.1 ± 1.16

13.14 ± 2.21

15.32 ± 2.51†

15.8 ± 0.62†

MCHC (g/dl)

30 ± 1.21

30.8 ± 2.44

32.9 ±1.39†

34.3 ± 0.43†

RBC (1012/l)

7.05 ± 1.01

6.99 ± 1.10

7.72 ± 0.3†

9.11 ± 0.15†

RDWc (%)

25.73 ± 2.24

24.71 ± 3.43

22.58 ± 2.9†

19.47 ± 2.23††

Biochemical parameters
Serum Iron (µg/dl)

102.74 ± 10.22†

109.52 ± 14.2†

124.7± 8.8††

139.53± 13.6†††

TIBC ((µg/dl)

405.43 ± 21.67†

399.5 ± 32.7†

393.22 ± 25.3†

354.81 ± 36.3††

25.3 ± 3.71††

29.47 ± 4.82††

31.86 ± 3.4†††

39.37 ± 2.2†††

13.13 ± 1.32

12.32 ± 2.54

% TS
LipidPeroxidation
[equivalent to MDA
conc. (nmol/ml)]

¶
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12.42 ± 1.8

11.37± 2.2

*The difference in all parameters (except lipid peroxidation) in MN+IN group animals after
treatment is significantly different from those before treatment.
¶

Not significant- There was no significant difference between lipid peroxidation levels at anemic
condition and post treatment in all groups.
IN- Iontophoretic treatment group, MN-Microneedle treatment group, MN+IN- Iontophoresis
combined with microneedle pretreatment and IP- FPP administered as intraperitoneal injection.
†p<0.05
††p<0.001
†††p<0.0001
3.3.1.4. Intraperitoneal delivery of FPP
FPP was administered intraperitoneally to rats for 2 weeks (positive control). There was a
significant improvement in all hematological and biochemical parameters in these animals at end
of treatment period. The improvement in the morphology of RBC in this group of animals is
evident in figure 3-4f.

Figure3-4. Representative pictures of morphology of RBCs (a) RBCs in healthy rats (b) RBCs of
anemic rats (Microcytic and hypochromic RBC shown with ↑marks) (c) RBCs in group 3
administered with FPP by iontophoresis (IN) (d) RBCs in rats administered with FPP following
microneedle (MN) pretreatment(group 4) (e) RBCs of the rats administered with FPP using
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combination of iontophoresis and microneedle pretreatment (MN+IN) (group 5) and (f) RBCsof
rats received FPP through IP injection (group 6).

3.4. CONCLUSIONS
FPP can be delivered via transdermal route using iontophoresis in combination with
microneedle pretreatment. The results of the study suggest that microneedle and iontophoresis
mediated delivery of iron via transdermal route could be developed as a potential treatment for
IDA. The transdermal controlled delivery of iron could become a potential, safe and effective
alternative to parenteral iron therapy.
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CHAPTER 4
SOLUBLE MICRONEEDLE SYSTEM FOR DELIVERY OF FPP
4.1. OBJECTIVES
1. Development and optimization of soluble microneedle systems for FPP using

poly(methylvinylether/maelic acid) (PMVE/MA) polymers.
2. Kinetic profiling for the FPP released from polymeric microneedle system in the skin.
3. Evaluation of safety and toxicity of FPP in human epidermal keratinocyte (HEK) and

dermal fibroblast (HDF) cell lines with the help of cell proliferation, viability, reactive
oxygen species, cytokines expression assays.
4.2. INTRODUCTION
Our main aim in this study was to develop a soluble microneedle system incorporated
with ferric pyrophosphate (FPP)to deliver iron with an objective to meet higher iron demand in
case of moderate and severe anemic conditions.Soluble microneedle systems consist of an array
of microneedles prepared using water soluble polymers loaded with the therapeutic agent
(FPP)andFPPwould be released into the dermal fluids upon penetration of the microneedles.
Development of a successful patient friendly, self-administrable dissolvable microneedle array
system for iron delivery can offer great advantages over oral and parenteral modes of
administration. From the previous study, the possibility of delivering iron in significant amounts
leading to reversal of iron deficiency anemia has been demonstrated in iron deficient rat model
[97].
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Ferric pyrophosphate (FPP) was incorporated into soluble microneedle arrays and
morphology of the prepared microneedles was evaluated. The microneedle system was subjected
to in vitro drug permeation studies across the hairless rat skin. In vivo cutaneous
microdialysisstudies were also carried out in hairless rats after insertion of soluble microneedles
prepared with FPP at two different concentrations. The safety of administered iron compound
was evaluated using human epidermal keratinocytes (HEK) and human dermal fibroblasts (HDF)
cell lines. Cell proliferation/viability,reactive oxygen species generation assays and proinflammatory cytokines assay were performed after exposing the cells with FPP at different
concentrations. Successful development of safe and effective soluble iron microneedle systems
will be of a great advantage in poor economic settings with minimum risk of contamination
issues and less discontinuation of iron therapy.
4.3. MATERIALS AND METHODS
4.3.1. Materials
Soluble Ferric pyrophosphate was obtained from Sigma-Aldrich Inc (St. Louis, MO).
Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained from EMD Chemicals
(Gibbstown, NJ). Ferrover® iron was purchased from Hach Company (Loveland, OH). Serum
iron & TIBC kit was procured from Cliniqa Corporation (San Marcos, CA). All other chemicals
and solvents used were of pure grade obtained from Fischer scientific (Fairway, NJ).
4.3.2. Methods
4.3.2.1. Preparation of soluble microneedles
Soluble microneedles containing FPP were prepared using water soluble polymers.
Aqueous blends containing 15% w/w poly (methylvinylether/maelicacid (PMVE/MA)
(Gantrez®AN-139, Ashland, Kidderminster, UK) and the relevant concentration of the FPP (143
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mg FPP/g formulation) were prepared and used to fabricate microneedle arrays using laser
engineered silicone micromold templates. The arrays were composed of 121 (11x11) needles
perpendicular to the base, of conical shape ranging in height between 450 and 600 μm with base
widths about ~300 μm. 300 or 600 mg of FPP and polymermixture was added into the laserengineered silicon microneedlemolds and subjected to centrifugation at 550 g for 15 min
followed by drying at room temperature for 48 h. Upon removal from the molds, the sidewalls of
the microneedle arrays were removed using a heated scalpel blade. An accurate measurement of
the final percentage of active compound in the device was determined based on mass loss
calculations following water evaporation from the arrays [Soluble microneedleswere prepared at
Dr. Ryan Donnelly research lab facility, Queen’s University Belfast, UK].
4.3.2.2. Morphology of soluble microneedles after insertion in the tissue
The disappearance/solubilization of microneedles was assessed by investigating the
change in morphology of the microneedles after insertion into the skin tissue. Scanning Electron
Microscopy (SEM) was used to obtain microneedles pictures to observe the change in
morphology. Microneedle arrays were inserted into rat skin with mild force using thumb. The
array was removed carefully after 1 hour and 3 hours and, SEM pictures were obtained. For
SEM, the microneedle arraywas fixed on aluminumstubs using glued carbon tapes and coated
with gold using Hummer 6.2 sputter coater (AnatechUSA, Union City, California). The sputter
coating chamberwas supplied with argon gas throughout the coating process.Photomicrographs
of the microneedle arrays were acquired using a model JSM-5600 scanning electron microscopy
(JEOLLtd., Tokyo, Japan).
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4.3.2.3 In vitro transdermal permeation of FPP
In vitro permeation studies were carried out across the hairless rat skin using Franz
diffusion cell set up. PBS adjusted to pH 5 using 1 N hydrochloric acid (HCl) was used as
receiver phase. The electrical resistance was measured to confirm the skin integrity as described
earlier. Briefly, a load resistor RL (100 kΩ) was loaded in series with skin and thevoltage drop
across the whole circuit and skin was measured with a voltage of 100 mV applied at 10 Hz to
obtain skin resistance in kΩ. After insertion of microneedles into the rat skin FPP permeation
studies were carried out for 24 hours. The amount of FPP permeated over time across the rat skin
was measured using inductively coupled plasma mass spectrometry (ICP-MS) [Thermo Fisher
Scientific, Waltham, MA].
4.3.2.4. In vivo cutaneous microdialysis studies
All animal studies were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Mississippi (Protocol # 11-016).Linear microdialysis probe (BASi,
WestLafayette IN) with 5 mm length and 30 kDa cut-off molecular weight was used to perform
dermal microdialysis studies. A 30G needle was inserted intradermallyparallel to the stratum
corneum surface, through a distance of 1 cm. Themicrodialysis probe was inserted through this
needle and the needle was withdrawn leaving the probeimplanted in the dermal tissue. The inlet
tube was connected to an injection pump (BASi, WestLafayette, IN) and the outlet was placed in
a sample collection vial.
4.3.2.4.1.Microdialysis probe recovery
Microdialysisprobe recovery studies were performed in vivousing retrodialysis method. A
flow rate of 2 μL/minwas chosen for the entire study. Microdialysis probe was equilibrated with
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PBS (pH-5) for 30 minutes and later, known concentration of drug was perfused and dialysate
was collected at different time points. The recovery was calculated using the following formula:

4.3.2.4.2. Cutaneous microdialysis studies
The microneedle array (with 43 mg and 86 mg of FPP) was applied on the rat abdominal
skin by firmly pressing them against the rat skin using thumb and the array was secured with the
help of a surgical tape. Dialysate fluid was collected every hour and the array was removed after
3 hours and microdialysis sampling was continued till 10 hours. The microdialysis samples were
analyzed using inductively coupled plasma mass spectrometry (ICP-MS).
4.3.2.5. Skin content analysis
Amount of FPP retained in the rat skin after 10 hours was analyzed by taking a biopsy
section of microneedle array application area. Skin surface was washed thoroughly with deionized water and wiped with alcohol swab to remove adhered FPP on the skin surface. The
biopsy section of the skin was minced into small pieces and the tissue was dissolved in 1 N
sodium hydroxide for 12 hours and homogenized to extract FPP into solution. The amount of
FPP presented in sodium hydroxide was measured using ICP-MS.
4.3.2.6. Evaluation of safety and toxicity of FPP in human skin cell lines
The safety studies were carried out using human epidermal keratinocyte (HEK) [HEK001
(ATCC® CRL-2404™)] continuous cell lines and human skin fibroblast (HDF) [CCD1093Sk
(ATCC® CRL2115™)] cell lines [ATCC, Manassas, VA].
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4.3.2.6.1. Cell culture
HEK cells were grown in Keratinocyte Serum Free Medium (GIBCO-BRL 17005042)
with 5 ng/ml human recombinant epidermal growth factor (EGF) and 2mM L-glutamine (without
bovine pituitary extract and serum) in cell culture flasks (75 cm2) to approximately 80%
confluence in 5% CO2 environment incubator maintained at 37 °C. HDF cells were grown in
Eagle's Minimum Essential Medium (EMEM) (ATCC-302003) with 10 % FBS in cell culture
flasks (75 cm2) to approximately 80% confluence in a 37°C, humidified 5% CO2 incubator. Both
the cell media were supplemented with penicillin (10000 units) and streptomycin (10 mg/mL)
solution. The cells were seeded into clear/black wall 96-well microplates at a density of 200,000
cells/ml (200 μL) and cell proliferation/viability assay, reactive oxygen species (ROS)
measurement assay and cytokines assays were performed. Cell count was obtained with Bio-Rad
automatic cell counter (Bio-Rad, Hercules, CA) after staining a 10 µl aliquot of cell suspension
with 10 µl of Trypan blue stain (0.4 %) [Life Technologies, Grand Island, NY]. The passage
number 78 was used for HEK cell lines, and passage number 6 for HDF cell lines in all the
experiments.
4.3.2.6.2. Cell viability/proliferation assay
Cell proliferation assay was carried out using the CellTiter 96®AQueous one solution
reagent (Promega, Madison, WI) which can be used to measure the number of viable cells by
colorimetric method. After reaching approximately 80% confluence of the cells in microplates,
the media in all the wells for both HEK and HDF cell lines was replaced with 100 μL of fresh
medium (without serum and penicillin streptomycin solution) and cell lines were exposed to 100
μL of either basal medium (control) or serial dilutions of FPP prepared at different
concentrations (250, 125, 62.5, 31.25, 15.62 and 7.81 mg/ml) or digitonin (positive control)
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[Promega, Madison, WI] prepared at different concentrations (60 µg/ml-1.87 µg/ml) with serial
dilutions for 24 hours. FPP solutions were prepared using basal medium and digitonin solutions
were prepared from a stock of 20 mg/ml using cell culture grade dimethylsulfoxide (DMSO)
[ATCC, Manassas, VA]. Untreated cells served as control in this study.
The CellTiter 96®AQueous one solution reagent was completely thawed in water bath at
37°C for 10 minutes before use and 40 µl of the this reagent was added to each well in the 96
well plate containing the cells and the plate was incubated at 37 °C in a humidified, 5 % CO2
atmosphere for 4 hours. After incubation the absorbance at 490 nm was recorded using
microplate Reader (SpectraMax® M5, Molecular Devices, LLC. Sunnyvale, CA). Testing at each
concentration of the FPP and positive standard was performed in triplicates.
4.3.2.6.3. Measurement of Reactive Oxygen Species (ROS) activity/oxidative stress markers
Possible generation of reactive oxygen species (ROS) and the intracellular ROS activity
upon treating both HEK and HDF cell lines with FPP at different concentrations were measured
using OxiselectTM intracellular ROS assay Kit (Cell Biolabs, San Diego, CA). After reaching
approximately 80% confluence in 96-well microplates, both the cell lines was treated with cell
permeable fluorogenic probe 2’,7’-dichlorodihydrofluorescin diacetate (DCFH-DA). Cells
loaded with DCFH-DA were washed gently with Dulbecco’s Phosphate-Buffered saline (D-PBS)
(Sigma Aldrich, St. Louis, MO) 2-3 times and 100μL of fresh medium was added to all the wells
along with 100μL of FPP prepared at different concentrations (250, 125, 62.5, 31.25, 15.62 and
7.81 mg/ml) or H2O2 (positive control) prepared at different concentrations (2000-62.5 µM) for
24 Hours. Later cells were washed 2-3 times with again with D-PBS and 100 μL of fresh
medium and 100μL of 2X cell lysis buffer was added. After 5 minutes of incubation, 150 μL of
this medium was transferred to a black wall 96-well plate and fluorescence was measured.
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Untreated cells served as control in this study. All the studies were performed in triplicates. The
results obtained were compared using a standard calibration curve plotted for 2’, 7’dichlorodihydrofluorescin (DCF) from 0.01 nM to 10 µM using both media.
4.3.2.6.4. Measurement of cytokines as inflammatory response
Levels of various pro-inflammatory cytokines generated in HEK and HDF cell lines after
addition of FPP at different concentrations for 24 hours was assayed using Quantibody® Human
Inflammation Array 1 kit (RayBiotech, Inc. Atlanta, GA). Quantibody® arrayuses the
multiplexed sandwich ELISA-based technology which can determine the concentration of
multiple cytokines simultaneously and accurately. In the present study, 10 human cytokines, IL1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, MCP-1,IFNγ and TNFα levels expressed in both the
cells were measured after cells were treated with FPP for 24 hours. Digitonin (30 µg/ml) and
hydrogen peroxide (H202)[1000 µM] were used as positive controls. After reaching
approximately 80% confluence of the cells in microplates, the media in all the wells for both
HEK and HDF cell lines was replaced with 100 μLof fresh medium (without serum and
penicillin streptomycin solution). Cells were exposed to 100 μL of either basal medium (control)
or serial dilutions of FPP prepared at different concentrations (250, 125, 62.5 and 31.25mg/ml)
for 24 hours. Untreated cells served as control in this study. The standard glass slide provided as
Quantibody® array was spotted with 16 wells ofidentical cytokine antibodies arrayed in
quadruplicates. Cell supernatant from each well of 96 microplates treated with samples or
standard were loaded into each well of the glass slide. After proper wash steps with the wash
buffers, detection antibody cocktail was added to each well and incubated for overnight. Later,
detection antibody cocktail was discarded and after proper wash steps Cy3 equivalent dyeconjugated streptavidin was added to each well and the glass slide was incubated in dark for
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overnight again. Glass slide was washed again and completely air dried and the signals were
visualized through use of a laser scanner equipped with a Cy3 wavelength (Axon GenePix) and
data was extracted. Quantitative data analysis was performed usingQuantibody® Q-Analyzer
software (RayBiotech, Inc. Atlanta, GA).
4.4. RESULTS AND DISCUSSION
4.4.1. Soluble microneedles of FPP
Soluble microneedle arrays incorporating two different FPP loads (with 43 mg and 86 mg
of initial FPP) were prepared successfully using aqueous blends of 15% w/w poly
(methylvinylether/maelic acid) (PMVE/MA) via laser-engineered silicone micromold templates
as described by Donnelly et al (2011) previously [98]. In case of microneedle arrays with 43 mg
FPP, final weight of the arrays was 36.2 ± 6.7 mg and for microneedle arrays loaded with FPP at
86 mg, the final weight of the arrays was 67.6 ± 20.6 mg. The final amount of FPP presented in
the arrays was estimated to be ~5.16 ± 1.1 mg and ~9.31 ± 1.93 respectively.

Amount of
FPP (g)

Weight after drying
(g)

0.043

Weight of polymer
and FPP matrix
loaded into mold
(g)
0.308 ± 0.010

0.11 ± 0.006

Final weight of
the array after
sidewalls
removed (g)
0.036 ± 0.006

0.086

0.590 ± 0.004

0.185 ± 0.036

0.0676 ± 0.020

Table 4-1. The mean weights of FPP polymer matrix loaded into microneedle molds initially,
after drying for 48 hours and final average weight of array after sidewalls removed. The values
represented are the average of n=30 ± S.D.
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4.4.2. Morphology of soluble microneedles
Morphology of the soluble microneedle array was investigated using scanning electron
microscope (SEM) and the prepared microneedles had an average height ~540 ± 50 μm with an
average base radius of 250 ± 5 μm and an average tip radius of 25 ± 5μm.

(a)

(b)

(c)

Figure4-1.Images of FPP soluble microneedles (a) Microneedle array on the investigators finger.
[Pictures were taken using Nikon Digital Camera (Nikon Inc., NY)] (b) SEM images of FPP
soluble microneedle arrays containing 121 microneedles (18X magnification) (b) microneedles
array visualized at 90X magnification.
4.4.3. Soluble microneedles in the skin
Microneedle arrays with FPP were inserted in the rat skin (each array in a different rat).
The time required for disappearance of microneedles in the array was visualized with the help of
SEM images. Few microneedle arrays were removed at 1 hour time point after insertion and few
other microneedle arrays after 3 hours and 4 hours. The removed arrays were sputter coated with
gold in argon supplied chamber and SEM photomicrographs were obtained. The morphology of
microneedles after 1 hour and 3 hours are shown in the figure 4-2. The microneedles were found
to be dissolved/disappearedin ~3-4 hours in the skin tissue fluid.
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Figure4-2*. SEM Images of FPP soluble microneedle arrays (a) Microneedles before insertion
into the skin (b) Microneedles inserted into the rat skin and removed at 1 hour time point (c)
Microneedles inserted into the rat skin and removed after 3 hours. Arrows indicate the position
of individual microneedles.
*All the mages were taken at 75X magnification and only 6 microneedles were focused to show
the time dependent disappearance of microneedles in the rat skin after insertion.
4.4.4. In vitro permeation studies of FPP
From the in vitro studies, a cumulative amount of 101.66 ± 6.9μgof FPP permeated in 24
hours across the rat skin from microneedle array (0.5 cm2) having ~5.16 ± 1.1 mg of FPP and
120.95 ± 16.2μg permeated from microneedle array (0.5 cm2) having ~9.31 ± 1.93 mg of FPP.
The amount of FPP permeated across rat skin was evaluated using inductively coupled plasma
mass spectrometry. There was no significant difference between the amounts of FPP permeated
across rat skin from the arrays with different FPP loads. The amount of FPP retained in the skin
at the site of microneedle array application was found to be 5.63 ± 2.36 µg/mg and 8.64 µg/mg
respectively.
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Figure 4-3. The Cumulative amount of FPP permeated across rat skin from soluble microneedles
containing ~5.2 mg of FPP (♦) and ~9.3 mg of FPP (■). The data points represented are the
average of n=3 ± S.D.
4.4.5. ICP-MS
Inductively Coupled Plasma Mass Spectrometry or ICP-MS is a popular an analytical
technique used for elemental determinations due to its superior detection capabilities. ICPMS combines a high-temperature ICP (Inductively Coupled Plasma) source with a mass
spectrometer. The sample is typically introduced into the ICP plasma as an aerosol and
the ICP source converts the atoms of the elements in the sample to ions. Once the ions enter the
mass spectrometer, they are separated by their mass-to-charge ratio by the quadrupole system
and detected by the mass spectrometer. The ions formed by the ICP discharge are typically
positive ions which is suitable and highly precise technique which can measure as less
aspicomolar concentrations of iron present in the sample.
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4.4.6. Cutaneous microdialysis studies
The recovery of FPP by the microdialysis probe in the cutaneous tissue was found to be
58.2 ± 4.6 %.

The amount of free iron present at the active application site in the skin was

measured as concentration in the dialysate fluid from cutaneous microdialysis studies. When the
microneedles were inserted for 3 hours, a gradual increase in the concentration of free iron was
observed up to 4 hours and the free iron concentration declined slowly in the next 6 hours.
When microneedle array loaded with ~5.2 mg of FPP (final amount), ~ 11 µg of FPP was
observed at 4 hours in the interstitial fluid, in case of microneedle array loaded with ~9.3 mg of
FPP (final amount), ~ 17 µg was observed at 4 hours in theinterstitial fluid. The amount of FPP
retained in the rat skin at the active application site was 6.48 ± 0.72 µg/mg and 7.89 ± 0.58
µg/mg respectively with the two FPP loads.

Figure4-4.Image showing in vivo cutaneous microdialysis on the abdominal part of the hairless
rat after application of soluble microneedle array.
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Figure4-5B.
Figure4-5. The time course of free FPP in the dermal interstitial fluid following the application
of soluble microneedles loaded with (A) ~5.2 mg of FPP and (B) ~9.3 mg of FPP. The data
points represented are the average of n= 4 ± S.D.
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4.4.7. Dermal kinetics of Iron
Omnipresence of iron in the physiological system offers a great challenge to quantify and
distinguish between the iron present in various metabolic pools. Once introduced into the system,
iron readily binds to transferrin protein and circulates as bound iron throughout the body until it
reaches bone marrow or reticuloendothelial pool.
Iron kinetics in the skin was extensively studied by various research groups in the pastand
has been well documented in the literature [99-106]. The aim of these studies was to measure
iron disposition and kinetics in the skin that was injected intradermally/intravenously after
coupling the iron source with detectable radioactive species. In their earlier studies, Weintraub et
al estimated that significant quantities of iron get excreted through the skin when Ferrous59citrate
was injected as iron source intravenously in healthy volunteers [99]. The whole body scintillation
measurements were made after intravenous injection of radioactive iron and 25% loss in total
radioactivity through whole body counts was reported. There was a net radioactivity loss of 8.5
% through feces and urine alone. From the results, authors concluded that the observed greater
loss in whole body countsother than the radioactivity loss in feces and urine (25 % vs 8.5 %)
might be through the skin and speculated that skin might be acting as an active excretory organ
for iron. To support the hypothesis, Ferrous59 citrate was injected via sub-dermal route in
another 6 healthy volunteers, and radio autographs prepared from the skin sections of active
application site. A selective localization of radioactivity in the epithelial cells of the epidermis,
sweat glands, sebaceous glands and hair follicles was observed. A significant radioactivity was
also observed in heat stimulated sweat collections and keratinocytes after scotch tape stripping of
the forearm at the injected site in these volunteers. No radioactivity was found in connective
tissue even though it might the site of tip of the needle while injecting the radioactive iron. In the
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intradermal injection group ~75-85% loss in radioactivity was observed in first two days with
concomitant rise and fall in plasma radioactivity and further a slow second rate of loss in
radioactivity with a half-life averaged from 54-110 days. Authors concluded that this secondary
slow loss of radioactivity might be due to the loss of iron through the sweat and skin shedding.
Later, Beamish et al performed a systemic study to measure iron clearance from the

skin[100]. 59Fe-Ferrous citrate used as iron source was injected into sub-epidermal tissue of the
volar aspect of the forearm to healthy volunteers and iron deficient subjects. In normal
subjects,59Fe activity at the site of injection showed a rapid decline initially following a slow rate
of disappearance thereafter, which is in agreement with earlier report by Weintruabet al. When
the activity was plotted on a logarithmic scale, three exponential component was identified with
an initial half-life about 30 minutes, second half-life of about one day (~19-29 hours) and a slow
and third half-life about 60 (47-74) days. In case of sub-dermal injection of radioactive iron to
iron deficient patients, the amount of iron cleared in the first rapid phase was less compared to
healthy population, confirming the availability of unsaturated transferrin at the site of injection in
this patient population group. In one patient, iron was injected after binding it with transferrin in
vitro and authors reported that very little iron was removed from the site of injection. From these
reports, it was concluded that iron injected into the skin was rapidly bound to transferrin till its
saturation capacity and rest of the iron was rapidly removed into blood stream. In the same study
a dose dependent clearance of iron was also identified confirming the saturation of transferrin at
the site of injection. In case of iron that is bound to transferrin in the interstitial pool,
approximately two-thirds was cleared with a half-life of about one day and remaining one-thirds
was disappeared slowly with a half-life of 60 days. With all these studies, authors speculated the
existence of an intracellular iron pool in the skin.
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Later, in their independent studies, Wasserman et al (1965) and Pollycoveet al (1966),
suggested the existence of labile iron pools in the physiological system other than the known red
cell pool and reticulo-endothelial pools from which iron feedback might occur [106,107].In
further investigations by Cavill and Jacobs et al in 1971, they proposed a two compartment
model for the transferrin bound iron the interstitial fluid [103]. From the interstitial iron pool,
significant amount of iron bound to transferrin entering into the skin cells (~1 %/ hr) and about
0.1 % of intracellular iron per hour was lost to back to the interstitial pool. Iron in the interstitial
fluid of the skin was mainly cleared by lymphatic drainage which was confirmed with clearance
studies of another protein, albumin from interstitial fluid. From these investigations, it is clear
that, when all iron was bound to transferrin, no evidence of rapid clearance of iron from the site
of injection and it can leave only through capillary bed or by lymphatic drainage. Based on the
findings of intracellular exchangeable iron pool in the skin, authors suggest that there might be
other large parenchymal pools existing in the other organs, which are indirectly in equilibrium
with the plasma pool.
From all the above investigations regarding the kinetics of iron in the skin that was
injected intradermally, it could be inferred that slowest phase of iron clearance from skin was
actually from the skin cells, i.e. the slow loss of intracellular iron to the interstitial fluid. The
usual turnover time of epithelial cells is ~26 days, but the mean half-life of third phase iron
clearance was observed as 67 days.Generally,DNA is conserved in the skin by extrusion from the
maturing cells and re-absorption by the basal layers. Cavil et al suggested that a similar
mechanism might be happening in case of iron that is entering the epithelial cells [104].
In the present study, from SEM experiments the microneedles were dissolved in the skin
within 3-4 hours. The FPP retained in the skin in both in vitroand in vivoconditions (~20-30 %
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loaded FPP in the array) suggesting that FPP might be releasing slowly from the microneedle
array by maintaining a depot in the skin. In case of cutaneous microdialysis studies, the amount
of free iron detected in the interstitial fluid was low, which could be due to the rapid binding of
iron by transferrin in the interstitial fluid and clearance of free iron into the systemic circulation
to bind transferrin in other metabolic pools.

Figure4-6. Iron disposition and expected pathways of iron disappearance from the skin. Most of
the iron from soluble microneedles was rapidly cleared as free iron into the systemic circulation
to bind transferrin in other metabolic pools and some iron might be bound to transferrin in
interstitial fluid. About one-third of transferrin bound iron in interstitial pool was entering into
skin cells. From the literature, interstitial fluid in the skin acts as an exchange pool for iron
between the skin cells and other metabolic pools.

4.4.8. Safety and toxicity studies in cell lines
4.4.8.1. Cell proliferation assay
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The CellTiter 96®AQueous ‘one solution’ assay was improvised from previous CellTiter
96® AQueous Assay which contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an
electron coupling reagent (phenazineethosulfate; PES). PES has enhanced chemical stability,
which allows it to be combined with MTS to form a stable solution. This MTS tetrazolium
compound (Owen’s reagent) is bioreduced by cells into a colored formazan product that is
soluble in tissue culture medium [107]. Formazan is produced by an amount of NADPH or
NADH dehydrogenase enzymes directly proportional to the number of living cells in culture as
measured at 490 nm [108].
The decrease in the absorbance indicated the decrease in the mitochondrial activity and
the HEK cells treated with FPP at various concentrations showed a dose dependent cell
proliferation being least at 250 mg/ml and highest at 7.81 mg/ml. There was a decrease in cell
viability at high concentration of FPP, which might be due to the high osmolarity of FPP solution
at these concentrations. But the low concentrations (31.2 mg/ml, 15.6 mg/ml and 7.8 mg/ml) of
FPP were relatively safe and the amount of FPP that was present in the microneedle arrays were
~5.2 mg and ~9.3 mg only. A similar trend was observed in HDF cell line also. In all these
studies cells weretreated with serial dilutions of high concentrations of FPP to determine the safe
and cytotoxic dose for further evaluations.
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Figure4-7. The mitochondrial activity (MTS activity) of (A) HEK and (B) HDF cells after 24 h
exposure to 100 µl of FPP (250-7.8 mg/ml) and digitonin [D] (60 µg/ml-1.87 µg/ml). Results are
combined from three independent exposures and expressed as mean (± S.D.).
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4.4.8.2. ROS assay
OxiselectTMintracelluar ROS assay kit measures hydroxyl, peroxyl, and other reactive
oxygen species activity within a cell. Upon addition to cells, the non-fluorescent DCFH-DA
permeates well across the cell membrane and once inside the cell DCFH-DA was rapidly
deacetylated by cellular esterases to 2’, 7’-dichlorodihydrofluorescin (DCFH), which is also nonfluorescent

in

nature.

DCFH

will

be

rapidly

oxidized

to

fluorescent

2’,

7’-

dichlorodihydrofluorescin (DCF-green fluorescence) in presence of reactive oxygen species. The
fluorescence intensity is proportional to the ROS levels within the cell cytosol. The amount of
DCF generated will be compared with the standard calibration curve obtained by using different
concentration of DCF using relative fluorescence units (RFU). The DCF detection sensitivity
limit of the kit is as low as 10 pM. Hydrogen peroxide used as positive control at different
concentrations and it generally crosses cell membranesreadily, might be through the aquaporins
in the cell[109]. Reactive oxygen species can cause oxidative stress at cellular level and
oxidative stress can activate NF-ĸB signaling pathway, stress-activated kinases,and such
activation could result in cell death by either apoptosis or necrosis [110]. From figure 9, the
generation of reactive oxygen species as relative florescence units after treating the cells with
FPP was compared with standards (H2O2). Even at high concentrations of FPP, the amount of
DCF generated as a measure of ROS was very low. A similar trend was observed in HDF cell
line also with even low levels of ROS generation after treatment with FPP at different
concentrations. Low levels of oxidative stress are thought to be beneficial, because it is a
necessary prerequisite for a number of normal metabolic pathways, especially those involving
signaltransductions [111].
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Figure4-8.Standard calibration curve for 2’, 7’-dichlorodihydrofluorescin (DCF) assay in
HEKand HDF media.
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Figure 4-9. Induction of reactive oxygen species (ROS) by FPP (250-7.8 mg/ml) or hydrogen
peroxide (HP) in (A) HEK and (B) HDF cells after 24 hours exposure. Results are combined
from three independent exposures and expressed as mean (± S.D.).
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Figure 4-10. Scheme of DCF assay (With kind permission from Cell Biolabs, San Diego, CA).
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4.4.8.3. Cytokines measurement
Cytokines are hormone like polypeptides which play a major role in the inflammatory
and immunoregulatory responses, apoptosis, cell growth and differentiation. They are involved
ininteractions between different cell types, cellular responses to environmentalconditions, and
maintenance of homeostasis. Quantibody®array used in this study uses a pair of cytokine specific
antibodies for detection, like a traditional sandwichbasedELISA.In detail, one standard glass
slide is spotted with 16 wells of identical cytokine antibody arrays. Each antibody, together with
the positive controls was arrayed in quadruplicate. Acapture antibody was first bound to the glass
surface. After incubation with thesample, the target cytokine was trapped on the solid surface. A
second biotinlabeleddetection antibody was then added, which recognizes a differentisotope of
the target cytokine. The cytokine-antibody-biotin complex then visualized through the addition
of the streptavidin-labeled Cy3equivalent dye using a laser scanner. By arraying multiple
cytokinespecific capture antibodies onto a glass support, multiplex detection ofcytokines in one
experiment is made possible using this kit.For cytokine quantification, knownconcentrations of
cytokine standards wereused to generate a standard curve for each cytokine.
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Figure4-11. An overview of the amount of cytokines detected in HEK and HDF cell line after
treating them with FPP at different concentrations (31.2-250 mg/ml), H2O2 (1000 µM) and
digitonin (30 µg/ml). Results are combined from three independent exposures and expressed as
mean (± S.D.).
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Figure4-12. Presence of cytokines in (A) HEK and (B) HDF cells after 24 h exposure to 100 µl
of FPP (31.25-250 mg/ml) and hydrogen peroxide (1000 µM) and digitonin (30 µg/ml). Results
are combined from three independent exposures and expressed as mean (± S.D.).
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Cytokines are hormone like polypeptides which play a major role in the inflammatory
and immunoregulatory responses, apoptosis, cell growth and differentiation. They are involved
ininteractions between different cell types, cellular responses to environmentalconditions, and
maintenance of homeostasis. Quantibody®array used in this study uses a pair of cytokine specific
antibodies for detection, like a traditional sandwichbasedELISA.In detail, one standard glass
slide is spotted with 16 wells of identical cytokine antibody arrays. Each antibody, together with
the positive controls is arrayed in quadruplicate. Acapture antibody was first bound to the glass
surface. After incubation with thesample, the target cytokine was trapped on the solid surface. A
second biotinlabeleddetection antibody was then added, which recognizes a differentisotope of
the target cytokine. The cytokine-antibody-biotin complex then visualized through the addition
of the streptavidin-labeled Cy3equivalent dye using a laser scanner. By arraying multiple
cytokinespecific capture antibodies onto a glass support, multiplex detection ofcytokines in one
experiment is made possible using this kit.For cytokine quantification, knownconcentrations of
cytokine standards wereused to generate a standard curve for each cytokine.

Figure4-13.Descriptive image to show the floor map of standard glass slide uses in Quantibody®
array along with the detection mechanism of cytokines (With kind permission from RayBiotech,
Atlanta, GA).
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Figure4-14.Experimental procedure (work flow) with Quantibody® array for detection of
cytokines (With kind permission from RayBiotech, Atlanta, GA).
Among the measured cytokines IL-1α, IL-6, IL-8 and TNFα are pro-inflammatory
cytokines and IL-4, IL-10 and IL-13 are anti-inflammatory cytokines. Keratinocytes produce
many cytokines constitutively or by an external stimulus. The pro-inflammatory cytokines
expressed by keratinocytes include IL-1α, IL-6, IL-8, TNFα and IFNγ and keratinocytes have
receptors for IL-4, IL-10 and IL-13 cytokines.
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Generation of pro-inflammatory mediators like IL-1α, IL-6, IL-8 and TNFα in human
epidermal keratinocytes upon treating these cells with toxic skin irritants was proven in the past
[110,111]. Among the 10 cytokines measured, only IL-1α, IL-6, IL-8 were expressed in
detectable quantities above confidence levels in HEK cells. Interleukin 1 is a pro-inflammatory
cytokine produced by activated macrophages. It also helps to activate T cells.IL-1α stimulates
furtherrelease of secondary mediators, including IL-8. IL-8promotes dendritic cells migration
and recruitment ofmonocytes and neutrophils as key steps in the initiationphase of cutaneous
inflammation [112].IL-8, a powerful neutrophilattractant and produced by keratinocytes after
externalstimuli by an irritant. IL-6 promotedkeratinocyte cell proliferation and over expression
might lead to toxicity in the skin. There was a dose dependent expression of these proinflammatory cytokines in HEK cell lines after exposing to FPP at different concentrations. The
concentrations of these expressed cytokines in samples were compared with positive
standards.With FPP at high concentrations, the production of IL-1α, IL-6, were observed in HEK
cell lines. There was no expression of IL- 8 in HEK with FPP but the positive standards
expressed IL-8. In HDF cells treated with FPP, there was only IL-6 expression, which is even
very low compared to the standards. Only FPP at a concentration of 250 mg/ml expressed
detectable quantities of IL-6, IL-8 and MCP-1 in HDF cells. From the above studies it is clear
that the FPP at tested concentrations was safe and not eliciting any inflammatory responses.
4.5. CONCLUSIONS
Soluble microneedle system for FPP for treatment of IDA will serve as a potential
alternative to oral and parenteral iron formulations. The ease of self-applicability and avoidance
of gastrointestinal side effects are the greatest advantages with iron soluble microneedle system.
The developed soluble microneedles were found to dissolve in the skin within 3-4 hours and the
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dissolved FPP is maintaining a depot in the skin to release the iron slowly over time. The safety
and toxicity studies on cell lines proved that the amount of FPP loaded in microneedle arrays was
safe and did not show any toxicity in HEK and HDF cell lines. With desired drug loading in the
soluble microneedle array system, dose individualization is possible based on the iron status of
the patient and carries great potential by avoiding undesired side effects.
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CHAPTER 5
MINIMALLY INVASIVE METHOD FOR DELIVERY OF
IRON-DEXTRAN VIA TRANSDERMAL ROUTE

ABSTRACT
Iron dextran colloidal solution is one among the very few US Food and Drug
Administration (FDA)-approved iron sources for parenteral administration. Parenteral route does
not allow frequent administration because of its invasiveness and other associated complications.
The main aim of this project was to investigate the plausibility of transdermal delivery of iron
dextran facilitated by microneedles, as an alternative to parenteral iron therapy. In the first part
of the project, microneedle pretreatment was explored for iron dextran delivery. In vitro
permeation studies were carried out using freshly excised hairless rat abdominal skin (after
pretreatment with solid microneedles) in a Franz diffusion apparatus. In vivo iron repletion
studies were carried out in hairless anemic rat model. The hematological and biochemical
parameters were measured periodically during treatment in these animals.In the second part of
the study, soluble microneedle system was developed by incorporating iron dextran along with
poly(methylvinylether/maelic acid) (PMVE/MA) polymers and in vitro studies were carried out
across hairless rat skin to study the iron dextran release from soluble microneedle arrays. In vivo
studies were carried out after application of soluble microneedles in healthy hairless rats and
biochemical parameters were measured till 24 hours. The results suggest that microneedlemediated delivery of iron dextran could be developed as a potential treatment method for iron73

deficiency anemia. Finally, the toxicity of iron dextran was evaluated using human skin cell
lines.
5.1.INTRODUCTION
Oral iron therapy remains as choice of first line treatment option for iron deficiency
despite its high rates of intolerance and non-adherence.Moreover oral iron salts are readily
available and inexpensive. Oral iron salts are not able to replenish iron stores rapidly to meet
ongoing losses of iron (blood) especially in case of chronic conditions [113, 114]. Intravenous
(i.v.) iron formulations are the preferred option for iron replacement therapy to meet greater iron
demands especially in patient undergoing routine hemodialysis. Moreover, parenteral iron
formulations are the only choice as an adjunct to erythropoietin stimulating agents (ESAs) in
patients undergoing dialysis and having nondialysis-associated chronic kidney diseases (CKD),
patients with inflammatory bowel syndrome (IBD) and for oncology patients receiving ESAs for
chemotherapy-induced anemia [115].
Among all the parenteral iron formulations; Iron dextran (Imferon®-Large molecular
weight iron dextran) was the only FDA approved parenteral formulation in US for almost 40
years (1954-1990s). In 1991, Imferon®was discontinued due to its high adverse events and later
a low molecular weight iron dextran [InFed (165 kDa) and DexFerrum (267 kDa)] was approved
for clinical use in 1992. Sodium ferric gluconate and iron sucrose injection are available from
1999 and 2000 respectively for clinical useas parenteral iron therapy. Ferumoxytolbecame
available from 2009 for iron replacement in patients with IDA and CKD and recently in 2013;
ferric carboxymaltose was also approved for use in US [115]. Even though these new
formulations were claimed to be safer than earlier formulations in few clinical trials, the
complete safety and toxicity profiles are not established to full extent yet.
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oxyhydroxidecomplexed with polymerized low molecular weight dextran. All i.v. iron agents
share the same core chemistry;the core of each particle is an iron-oxyhydroxide gel which is
surrounded by a shell of carbohydrate that stabilizes the iron-oxyhydroxide; slows the release of
bioactive iron and maintains the resulting particles in colloidal suspension [116].
Iron dextran complex was extensively studied clinically for parenteral therapy to treat
iron deficiency anemia. Iron dextran is commercially available as stable, clear, viscous and
reddish-brown colloidal suspension containing 5% iron and 20% dextran [117]. Iron dextran is
the preferred formulation among the all i.v. colloids due to its established safety profile and
unlike other parenteral formulations; iron dextran is the only parenteral formulations approved
for intramuscular injection, i.v. bolus injection and total dose infusion as well. Total dose
infusion has been associated with a higher incidence of adverse events like hypotension,
arthralgias, myalgias, abdominal pain, nausea, and vomiting. A test dose is needed for all i.v.
iron formulations and patient should be monitored for at least 1 hour for adverse reactions [116].
Parenteral iron dextran administration is also associated with immediate adverse effects such as
dyspnea, abdominal or back pain, nausea and vomiting, fever and utricaria [118]. Fatal
anaphylactic reactions were also reported with iron dextran therapy [119-120, 45]. Generally,
parenteral iron therapy is considered to be safe and efficacious, but repeated administration could
potentially results in toxic amounts of free iron in the blood, sometimes even could prove fatal.
Slow and prolonged delivery of iron has been suggested as the best suited way to avoid super
saturation of iron carrier protein, transferrin, and to control iron stores in the systemic circulation
[75].
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Transdermal administration is generally intended for delivery of drugs across the skin
over long duration simulating slow intravenous infusion [121]. However, transdermal delivery of
therapeutic agents is limited due to high molecular weight (> 500 Da) and high hydrophilicity
[122]. Chemical enhancers are known to possess limited ability to enhance the permeation of
larger molecular weight therapeutic molecules. Use of microneedles is of great interest in recent
days due to their unique ability to facilitate the delivery of macromolecules and colloidal drugs
across the skin [123, 124]. Microneedles can create micro conduits for transport of drug
molecules across the stratum corneum [81]. In the current study, the feasibility of transdermal
delivery of irondextran using microneedles was investigated. Successful delivery of iron dextran
via transdermal route could be a potential option for treating iron deficiency anemia.
5.2. MATERIALS AND METHODS
5.2.1 Materials
Iron dextran (50 mg/mL) was purchased from sigma-aldrich (St. Louis, MO). AdminPen
600 device was purchased from nanoBio Sciences LLC, Almeda, CA. Phosphate buffered saline
(PBS, pH 7.4) premixed powder was obtained from EMD Chemicals (Gibbstown,
NJ). Ferrover® iron reagent was obtained from Hach Company (Loveland, OH). Serum iron &
TIBC kit is obtained from Cliniqa Corporation (San Marcos, CA) and all other chemicals were
obtained from Fischer scientific (Fairway, NJ).
5.2.2 Methods
5.2.2.1 Preparation of rat skin
Male hairless rats were used in both in vitro and in vivo studies, obtained from Charles
River, Wilmington, MA, USA. All the animals were of eight weeks old and weighing between
250-300 g. For the preparation of rat skin, animals were asphyxiated with CO2 and abdominal
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skin was excised, subcutaneous fat was removed and the skin pieces were cleaned carefully with
normal saline. The rat skin was used on the same day for all in vitro experiments. All animal
studies were approved by the Institutional Animal Care and Use committee (IACUC) at the
University of Mississippi (Protocol # 10-013 & # 11-016).
5.2.2.2 Measurement of hydrodynamic radius of iron dextran
Particle size (hydrodynamic radius) of the iron dextran colloid was measured by dynamic
light scattering (DLS) or photon correlation spectroscopy technique using Zetasizer 3000HSA
(Malvern Instruments Ltd, Westborough, MA).
5.2.2.3 General in vitro experimental setup
In vitro studies were carried out in vertical Franz Diffusion Cell apparatus (Logan
Instruments, Boston, MA). The rat skin was sandwiched between the donor and receiver
compartment of Franz diffusion cell, with stratum corneum facing the donor compartment of the
cell. The active diffusion area was 0.64 cm2. The AC electrical resistance of skin was measured
with the help of an electric circuit consisting of a digital multimeter and waveform generator
(Agilent Technologies, Santa Clara, CA) having a load resistor R L (100 kΩ) in series with the
skin. The voltage drop across the whole circuit (V0) and across the skin (Vs) was measured and
skin resistance was determined by applying a voltage of 100 mV at 10 Hz in the circuit. Skin
pieces with a resistance of ≥20 kΩ/cm2 were considered for permeation studies [125].
5.2.2.4. In vitro transdermal permeation studies
5.2.2.4.1 Permeation of iron dextran
After measuring electrical resistance of the skin, the donor compartment was filled with
200µL of 50 mg/mL iron dextran solution and receiver compartment was filled with 5 mL of
freshly prepared phosphate buffered saline (pH 7.4). During all in vitro permeation studies, the
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temperature of receiver compartment was maintained at 37±1°C by water circulation. Permeation
studies were carried out for 6 hours and one ml samples were collected from the receiver
compartment at predetermined time intervals (0, 1, 2, 3, 4, 5 and 6 h). Amount of iron permeated
into the receiver compartment across skin was determined with the help of EZ201 UV
spectrophotometer (Perkin Elmer, Waltham, MA) using FerroVer® iron reagent at 510 nm.
To study the effect of microneedle pretreatment on the permeation of iron dextran,
freshly excisedhairless rat skin was pretreated with AdminPen 600 stainless steel microneedles,
having an area of 1cm2 containing 187 microneedles with height of 500 µm, for two minutes
before mounting on the Franz diffusion apparatus.
5.2.2.4.2. Iron dextran retained in the skin
After in vitro permeationstudy, the active diffusion area (0.64 cm2) was excised with
biopsy punch and the surface was washed thoroughly with normal saline, to ensure complete
removal of any iron dextran adhering to the skin surface. The biopsied skin was then cut into
small pieces and homogenized in a vial containing 5mL of 1N sodium hydroxide (NaOH) and
incubated at 37˚C for 24hrs with intermittent shaking. The solutions were centrifuged to remove
any interfering substance and supernatant was collected and analyzed for iron content.
5.2.2.5. Iron repletion studies in anemic rats
5.2.2.5.1. Induction of iron deficiency anemia in rats
In vivo studies were performed in hairless rats. The animals were housed in conventional
cages with 12:12 hour day: light cycles maintained in the facility, during the entire study period.
Rats (n=18) were on normal diet and were allowed to adapt to the study environment for one
week. Initially 200 µl of blood samples were collected in EDTA (ethylenediaminetetraacetic
acid) coated Microvette® tubes (Sarstedt, Newton, NC) and 0.5 ml of blood was collected into
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1.5 ml centrifuge tubes (Eppendorf, Hauppauge, NY) from all animals by retro orbital bleeding
method. Blood samples collected in EDTA coated tubes were analyzed for hematological
parameters like hemoglobin (Hb), hematocrit (HCT), red blood cells (RBC), mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin
concentration (MCHC) using VetScanHM2 hematology system (Abaxis, Union city, CA). Serum
was separated from blood sample collected in centrifuge tubes and analyzed for biochemical
parameters like serum iron (SI), total iron binding capacity (TIBC) and % transferrin saturation
(%TS) (Basal values in healthy normal rats). Following initial screening, rats were fed withlow
iron content diet (~2-6 ppm, Harlan laboratories, Madison, WI) till the end of study. Iron
deficiency was induced in rats in 5 weeks since the inception of custom made low iron diet
which was further confirmed by measuring the blood hemoglobin and hematocrit values. The
anemic rats were divided into intact skin (control), microneedle pretreated, and intraperitoneal
(i.p.) groups (n=6) depending on the mode of delivery of iron.
5.2.2.5.2. Delivery of iron dextran, in vivo
Animals in the control and microneedle pretreatment group were anesthetized using
ketamine + xylazine (80+10 mg/kg) via intra peritoneal route. In case of control group animals, a
transdermal patch loaded with 200 µL of 50 mg/mL iron dextran was placed on the dorsal side of
the rat for 6 hrs. For microneedle pretreated group, rats were pretreated with AdminPen 600
microneedles (10 cm2)on dorsal surface for 2 minutes followed by the application of a
transdermal patch, loaded with 200 µL of 50 mg/mL iron dextran solution for a period of 6
hours. The treatment was continued for 3 weeks on alternate days. The third group
(intraperitoneal group) of animals was administered with 100 µl of iron dextran solution (10
mg/ml) in saline via intraperitoneal route on alternate days for 3 weeks. Blood samples were
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drawn from animal in all groups intermittently and at the end of treatment period and
hematological and biochemical parameters were evaluated.
5.2.2.5.3. Red blood cell morphology
Blood samples were withdrawn from rats at healthy, anemic and post treatment
conditions, from all the three groups and the red blood cells (RBC) were visualized under high
resolution optical microscope to study their cell morphology. In brief, a drop of venous blood
was collected and smears were prepared by wedge slide method and stained using WrightGiemsa stain. The RBCs were visualized with oil immersion using high resolution light
microscope (Axiolab A1, Carl Zeiss, USA) at 100x magnification. Images of RBCs were
captured using Carl Zeiss camera attached to the microscope.
5.2.2.6. Preparation of soluble microneedles
Soluble microneedles containing iron dextran were prepared using water soluble
polymers. Aqueous blends containing 15% w/w poly (methylvinylether/maelic acid
(PMVE/MA) (Gantrez®AN-139, Ashland, Kidderminster, UK) and the relevant concentration of
iron dextran (3 mg and 5 mg of iron in 300 and 600 mg of matrix respectively) were prepared
and used to fabricate microneedle arrays using laser engineered silicone micromould templates
[98]. The arrays were composed of 121 (11x11) needles perpendicular to the base, of conical
shape ranging in height between 450 and 600 μm with base widths about ~300 μm.
5.2.2.7.Morphology of microneedles
Morphology of microneedles was evaluated with the help of Scanning Electron
Microscopy (SEM) studies. Briefly, the microneedle array was fixed on aluminum stubs and
using glued carbon tapes and coated with gold using Hummer 6.2 sputter coater (Anatech USA,
Union City, California). The sputter coating chamber was supplied with argon gas throughout the
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coating process. Photomicrographs of the microneedle arrays were acquired using a model JSM5600 scanning electron microscopy (JEOL Ltd., Tokyo, Japan).
5.2.2.8. In vitro permeation studies of iron dextran
In vitro permeation studies were carried out across hairless rat skin using Franz diffusion
cell set up as described earlier in section 2.2.4.1. After insertion of microneedles into the rat skin
iron dextran permeation studies were carried out for 24 hours. The amount of iron dextran
permeated over time across rat skin was measured using inductively coupled plasma mass
spectrometry (ICP-MS) [Thermo Fisher Scientific, Waltham, MA]. The amount of iron retained
at the active microneedle array application site was also measured.
5.2.2.9. In vivo studies in hairless rats
In

vivo

studies

were

carried

out

in

hairless

rats

(n=6).

Only

microneedlearraysincorporated with high drug load of iron dextran (~430 µg of elemental iron)
was used for in vivo studies. Rats were divided into control group and treatment group. In
treatment group, the microneedle arrays were applied by firmly pressing them against the rat skin
using thumb and the array was secured with the help of a surgical tape. Microneedle array was
removed after 12 hours and blood samples were collected from animals every 3 hours, starting
from 0 hour till 24 hours. Biochemical parameters like serum iron, total iron binding capacity
(TIBC) and % transferrin saturation (%TS) were measured using Serum iron & TIBC kit. A
control group was included with transdermal application of iron dextran solution for 12 hours.
5.2.2.10. Evaluation of safety and toxicity of iron dextran in human skin cell lines
The safety studies of iron dextran were carried out using human epidermal keratinocyte
(HEK) [HEK001 (ATCC® CRL-2404™)] continuous cell lines and Human Skin Fibroblast
(HDF) [CCD1093Sk (ATCC® CRL2115™)] cell lines [ATCC, Manassas, VA].
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5.2.2.10.1. Cell culture studies
HEK cells were grown in keratinocyte serum free medium (GIBCO-BRL 17005042) with
5 ng/ml human recombinant epidermal growth factor (EGF) and 2mM L-glutamine (without
bovine pituitary extract and serum) in cell culture flasks (75 cm2) to approximately 80%
confluence in 5% CO2 environment incubator maintained at 37 °C. HDF cells were grown in
Eagle's Minimum Essential Medium (EMEM) (ATCC-302003) with 10 % FBS in cell culture
flasks (75 cm2) to approximately 80% confluence in 5% CO2 incubator at 37°C. Both the cell
media were supplemented with penicillin (10000 units) and streptomycin (10 mg/mL)
solution.The cells were seeded into clear/black wall 96-well microplates at a density of 200,000
cells/ml (200 μL) and cell proliferation/viability assay, reactive oxygen species (ROS)
measurement assay and cytokines assays were performed. Cell count was obtained with Bio-Rad
automatic cell counter (Bio-Rad, Hercules, CA) after staining an aliquot of cell suspension (10
µl) with 10 µl of Trypan blue stain (0.4 %) [Life Technologies, Grand Island, NY]. For HEK cell
lines, passage number 78 and for HDF cell lines, passage number 6 were used in all the
experiments.
5.2.2.10.2. Cell viability/proliferation assay
Cell proliferation assay was carried out using The CellTiter 96®AQueous one solution
reagent (Promega, Madison, WI) which can be used to measure the number of viable cells by
colorimetric method. After reaching approximately 80% confluence of the cells in microplates,
the media in all the wells for both HEK and HDF cell lines was replaced with 100 μL of fresh
medium (without serum and penicillin streptomycin solution).Cell lines were exposed to 100 μL
of either basal medium (control) or serial dilutions of iron dextran prepared at different
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concentrations (10, 5, 2.5, 1.25, 0.62 and 0.31 mg/ml) or digitoninsolution (positive control)
[Promega, Madison, WI] prepared at different concentrations (60 µg/ml-1.87 µg/ml) with serial
dilutions for 24 hours. Iron dextran solutions were prepared in basal medium and digitonin
solutions were prepared from a stock of 20 mg/ml using cell culture grade dimethylsulfoxide
(DMSO) [ATCC, Manassas, VA]. Untreated cells served as control in this study. The CellTiter
96®AQueous one solution reagent was completely thawed in water bath at 37°C for 10 minutes
before use and 40 µl of this reagent was added to each well in the 96 well plate containing the
cells and the plate was incubated at 37 °C in a humidified, 5 % CO2 atmosphere for 4 hours.
After incubation the absorbance at 490 nm was recorded using microplate Reader (SpectraMax ®
M5, Molecular Devices, LLC. Sunnyvale, CA). Testing at each concentration of the iron dextran
and positive standard was performed in triplicates.
5.2.2.10.3. Measurement of Reactive Oxygen Species (ROS) activity/oxidative stress
markers
Possible generation of reactive oxygen species (ROS) and the ROS activity intracellularly
upon treating both HEK and HDF cell lines with iron dextran at different concentrations was
measured using OxiselectTM intracellular ROS assay kit (Cell Biolabs, San Diego, CA). After
reaching approximately 80% confluences in 96-well microplates, both the cell lines were treated
with cell permeable fluorogenic probe 2’, 7’-dichlorodihydrofluorescin diacetate (DCFH-DA).
Cells loaded with DCFH-DA were washed gently with Dulbecco’s Phosphate-Buffered Saline
(DPBS) (Sigma Aldrich, St. Louis, MO) 2-3 times and 100μL of fresh medium was added to all
the wells and treated with 100μL of iron dextran prepared at different concentrations (10, 5, 2.5,
1.25, 0.62 and 0.31 mg/ml) or hydrogen peroxide (H2O2) (positive control) prepared at different
concentrations (2000-62.5 µM) for 24 Hours. Later cells were washed 2-3 times again with
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DPBS and 100 μL of fresh medium and 100μL of 2X cell lysis buffer was added. After 5
minutes of incubation, 150 μL of this medium was transferred to a black wall 96-well microplate
and fluorescence was measured. Untreated cells served as control in this study. All the studies
were performed in triplicates. The results obtained were compared using a standard calibration
curve plotted for 2’, 7’-dichlorodihydrofluorescin(DCF) from 0.01 nM to 10 µM using both
media.
5.2.2.10.4. Measurement of cytokines as inflammatory response
Levels of various pro-inflammatory cytokines generated in HEK and HDF cell lines after
addition of iron dextran at different concentrations for 24 hours was assayed using Quantibody®
Human Inflammation Array 1 kit (RayBiotech, Inc. Atlanta, GA). Quantibody® array uses the
multiplexed sandwich ELISA-based technology which can determine the concentration of
multiple cytokines simultaneously and accurately. In the present study, 10 human cytokines, IL1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, MCP-1, IFNγ and TNFα levels expressed in cell lines
were measured after cells were treated with iron dextran for 24 hours. Digitonin (30 µg/ml) and
H202 (1000 µM) were used as positive controls. After reaching approximately 80% confluence,
the media in all the wells for both HEK and HDF cell lines was replaced with 100 μL of fresh
medium (without serum and penicillin streptomycin solution) and cell lines were exposed to 100
μL of either basal medium (control) or serial dilutions of iron dextran prepared at different
concentrations (10, 5, 2.5. 1.25 mg/ml) for 24 hours. Untreated cells served as control in this
study. The standard glass slide provided as Quantibody® array was spotted with 16 wells of
identical cytokine antibodies arrayed in quadruplicate. Cell supernatant from each well of 96
microplate (samples) or standard were loaded into each spotted well of the glass slide. After
proper wash steps with the wash buffers detection antibody cocktail was added to each
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spottedwell and incubated for overnight. Later, detection antibody cocktail was discarded and
after proper wash steps Cy3 equivalent dye-conjugated streptavidin was added to each well and
the glass slide was incubated in dark for overnight again. After incubation, glass slide was
washed again and completely air dried and the signals were visualized through use of a laser
scanner equipped with a Cy3 wavelength (Axon GenePix) and data was extracted. Quantitative
data analysis was performed using Quantibody® Q-Analyzer software (RayBiotech, Inc. Atlanta,
GA).
5.2.3 Statistical analysis
GraphPadInStat 3 software was used for statistical analysis. One-way ANOVA was used
to determine the level of significance for correlation between parameters and P < 0.05 was
considered as the significant difference. Unpaired t-test was used to determine the level of
significance for correlations in absorbance and florescence values observed in cell studies
between iron dextran and positive controls. A significance level of p< 0.05 was considered as
statistically significant.
5.3. RESULTS AND DISCUSSION
Skin is known to be a formidable barrier to the penetration of large molecular size
therapeutic agents [122]. However, certain studies have demonstrated permeation of
macromolecular substrates across the skin [126]. Some reports even demonstrated the
penetration of particulate drug delivery systems ranging from nanometer to micrometer size
[127, 128] into the skin. Recently, Sonavane and co-workers have demonstrated the in vitro
delivery of gold nanoparticles of various sizes across rat abdominal skin. The authors reported
that, nanoparticles with average size of 15nm permeated across rat abdominal skin in
significantly higher amounts than those of 102nm and 198nm at the end of 12h. The X-ray
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spectroscopy studies revealed deeper localization of 15nm size particles than the larger particles
[129].
The hydrodynamic diameter of iron dextran was measured using DLS technique and
found to be ~ 14 nm. In the present study even at the end of 12 h (data shown up to 6 h) there
was no iron dextran detected in the receiver compartment indicating practically no permeation
across the rat skin. Moreover, there was no iron dextran detected in the skin either. Despite all
the in vitro experimental conditions being similar, it is still unknown at this stage, the reasons for
conflicting observation between our studies and the studies by Sonavane and co-workers.
Recently, iontophoresis has been shown to enhance the dermal penetration and
permeation of particulate substances even up to the size of ~100 nm [130, 131]. In the present
study, even application of a constant electrical current (both anodal and cathodal) at 0.5 mA/cm2
could not enhance the permeation of colloidal iron dextran across the abdominal rat skin (data
not shown). It is likely that at this current density, the electrophoretic driving force is not strong
enough to drive the colloidal particles of huge mass.
So far, many research groups have studied the effect of microneedles on the transdermal
delivery of a wide range of molecules with different physico-chemical properties [132-135].
Microneedles are micron sized needles and have the potential to deliver micro and macro
molecules across the skin without causing significant pain [136]. The effect of microneedles on
delivering both small and large molecules including proteins, peptides and genes into the skin
was explored in the past [81, 132, 135&137]. Several reports exist on the delivery of particulate
systems utilizing microneedles via transdermal route. Kohli and Alpar demonstrated that,
nanoparticles of 50 nm or less in size can penetrate into the skin layers [138]. Therefore, the
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effect of microneedle pretreatment of skin on the permeation of iron dextran was investigated in
this study.
5.3.1 In vitro permeation of iron dextran
In vitro permeation studies of iron dextran were carried out for 6 hours after pretreating the rat
skin with AdminPen 600 microneedles for 2 minutes. The cumulative amount of iron dextran
permeated at the end of 6th hour was found to be 10.28 ± 0.45µg/cm2 (Figure5-1). After the
completion of in vitro permeation studies for 6 hours, 2.48µg/mg of iron dextran was found to
have retained in the skin. In vitro permeationstudies concluded that microneedle pretreatment
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Figure5-1.In vitro permeation studies of Iron dextran across the (■) intact hairless rat skin
(control) and (▲) skin pretreated with microneedles.
5.3.2. Iron repletion studies in anemic rats
Initially, healthy animals were checked for all hematological and biochemical parameters
and recorded as basal values.Iron deficiency anemia was induced in all animals (n=18) by
feeding low iron diet for five weeks. There was a significant change in the hematological
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parameters, indicating successful induction of anemia. The first step in the typical diagnosis of
iron deficiency anemia includes measuring the hemoglobin levels in the blood. Along with
hemoglobin levels, measurement of MCV, HCT and other red blood cell indices are critical in
assessing the status of iron deficiency anemia. Hematocrit measures the percent volume of red
blood cells in unit volume of whole blood. MCV gives the average volume and size of red blood
cell and in case of iron deficiency condition; microcytic and hypochromic erythrocytes are
usually observed. The RBC morphology in iron deficient rat clearly shows the presence of
microcytic RBC (figure 5-3b). MCH is the average mass of hemoglobin in red blood cell and
MCHC is the measure of concentration of hemoglobin in a given volume of packed red blood
cells. The red cell distribution width is a measure of the variation of red blood cell width and is
used in combination with the mean corpuscular volume in differential diagnosis of various other
anemic conditions. In this study, the mean hemoglobin and RBC values at healthy condition was
14.43 ± 0.81g/dLand 8.59 ± 0.44*1012/L respectively were found to decrease to 10.06 ±
1.05g/dL and 6.32 ± 0.59 *1012/L when the rats were induced anemic condition.
Serum samples were analyzed for biochemical parameters. The average values of serum
iron before and after inducing anemia were found to be 187.96 ± 3.04 µg/dL and 91.20 ± 10.58
µg/dL, respectively. The TIBC values increased from 351.60 ± 16.64 µg/dL to 556.90 ± 58.39
µg/dL. There was a decrease in mean % TS from 42.43 ± 3.12 to 16.01 ± 0.76 after inducing
anemia compared to healthy state. Serum iron and %TS decreased significantly, while the TIBC
values increased after inducing anemia. Serum iron measures the transferrin bound iron in blood
and TIBC measure the amount of transferrin that is still available to bind and transport iron. %TS
gives the ratio of SI to TIBC which is an accurate measurement compared to individual

88

measurements of SI and TIBC. Mean values of other hematological parameter of healthy and
anemic condition of all the rats (n=18) are shown in table 5-1.

5.3.2.1 Transdermal delivery of iron dextran, in vivo
The anemic rats were divided into three groups and were treated with iron dextran using
different modes of delivery. Polyolefin foam patch of area 10 cm2 was loaded with 200 µL of
iron dextran solution and placed on the dorsal surface of the rats in case of control group.
Whereas, in case of microneedle pretreatment group, the dorsal surface of the rat was pretreated
with AdminPen 600 microneedles for 2 minutes and then the patch was placed on the treated
surface for six hours.
The treatment was continued for 3 weeks on alternate days. Blood samples were collected
by retro-orbital bleeding and all hematological and biochemical parameters were evaluated at the
end of 2nd and 3rd week. In case of control group, the hematological or biochemical parameters
turned out to be severely poor at the end of 2nd week. This indicates that, there is no feasibility of
delivery of iron dextran via passive transdermal delivery without microneedle pretreatment.
Therefore, the passive transdermal delivery treatment was not continued to prevent endangering
the lives of rats. However, in case of microneedle pretreated group, there was a significant
improvement in all the parameters at the end of 3rd week. The mean biochemical parameter
values, prior to inducing anemia, after inducing anemia, after treatment with iron dextran in case
of microneedle pretreated group and intraperitoneal injection group are shown in figure 5-2.
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Figure 5-2.The mean values of all biochemical parameters, prior to inducing anemia (Normal),
after inducing anemia (Anemic), after treating with iron dextran (microneedle pretreatment (IDMN)) and treatment with intraperitoneal injection of iron dextran (ID-IP).
The mean hemoglobin value of 10.36 ± 0.57 g/dL at anemic condition increased to 13.96
± 0.51 g/dL in microneedle pretreated group. An increase in the hemoglobin level of 1 g per dL
for every two to three weeks is considered as an effective iron replacement therapy [139, 14].
The mean SI, TIBC and %TS at the end of study in case of microneedle treated group were
found to be 137.63 ± 8.07 µg/dL, 334.23 ± 6.14 µg/dL and 39.03±4.75 %, respectively (figure52). Mean values of all hematological parameters are shown in table 5-1.There was significant
improvement in the morphology of RBCs in microneedle treatment group of rats compared to
anemic condition (Figure5-3c).
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(a)

(c)

(b)

(d)

Figure 5-3.Representative pictures of morphology of RBCs (a) RBCs in healthy rats (b) RBCs of
anemic rats (arrow marks point the microcytic and hypochromic RBC) (c) RBCs of rats treated
with iron dextran following microneedle pretreatment and (d) RBC of rats received iron dextran
through intraperitoneal injection.
5.3.2.2. Intraperitoneal delivery of iron dextran
Iron dextran was administered via intraperitoneal route on alternate days to one of the
groups to serve as positive control. There was statistically significant improvement in all the
biochemical and hematological parameters in the positive control group. The mean SI, TIBC and
%TS values at the end of study was found to be 147.30 ± 15.56 µg/dL, 366.90 ± 14.07
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µg/dLand 40.29 ± 5.78 % followed by IP injection of iron dextran (Figure5-2). All other
hematological parameters are shown in the table 5-1.
After
Intraperitone
microneedlepr
al group
etreatment
13.96 ± 0.51
14.5 ± 0.22

Hematological
Parameter

Healthy rats

Anemic
condition

Hemoglobin (g/dL)

14.43 ± 0.81

10.06 ± 1.05

RBC (*1012/L)

8.59 ± 0.44

6.32 ± 0.59

10.25 ± 0.95

10.32 ± 0.25

Hematocrit (%)

42.65 ± 1.28

33.24 ± 3.37

41.87 ± 4.98

41.48 ± 0.91

55.33 ± 4.12

45.31 ± 3.07

41.33 ± 2.25

46.03 ± 2.02

19.30 ± 1.58

14.93 ± 0.68

14.86 ± 0.68

18.30 ± 0.75

35.39 ± 0.87

30.00 ± 1.83

32.03 ± 2.21

34.01 ± 0.73

16.47 ± 0.81

15.47 ± 3.87

16.73 ± 1.50

17.73 ± 0.73

Mean Corpuscular
Volume (fL)
Mean Corpuscular
hemoglobin (pg)
Mean Corpuscular
hemoglobin
concentration (g/dL)
Red blood cell
distribution width
(%)

Table 5-1. The mean values of hematological parameters, prior to inducing anemia (healthy),
after inducing anemia, after treating with iron dextran in case of microneedle pretreatment and
after treating with iron dextran via intraperitoneal route.

Iron dextran is known to be readily uptaken by the reticuloendothelial system from the
intravascular fluid compartments and processed to make the iron available to the body for
different biochemical and physiological needs [115]. Treatment of iron deficiency with iron
dextran solution via intravenous route is well established [140]. In the present study, the levels
of hemoglobin and other parameters were close to that of normal condition (baseline values) at
the end of 2nd week in case of positive control group (IP). On the other hand, in case of
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microneedletreated group biochemical and hematological parameters were statistically
significant from its basal levels at the end of third week after treatment initiation.
5.3.3. Soluble iron dextran microneedles
Soluble microneedle arrays incorporating two different iron dextran loads (with 3 mg and
5 mg of initial drug loads) were prepared successfully using aqueous blends of 15% w/w poly
(methylvinylether/maelic acid) (PMVE/MA) via laser-engineered silicone micromould templates
as described by Donnelly et al (2011) previously [98]. In case of microneedle arrays with 3 mg
drug load, final amount of elemental iron presented in the arrays was estimated to be ~260 µg
and for microneedle arrays with 5 mg drug load, final amount of elemental iron presented in the
arrays was ~430 µg.
5.3.4 Morphology of soluble microneedles
The prepared microneedles have an average height of ~550 ± 60 μm with an average base
radius of 250 ± 10 μm and an average tip radius of 25 ± 5 μm.

Figure5-4. SEM images of iron dextran soluble microneedle arrays. (a) microneedles array
containing 121 microneedles (18Xmaginification) (b) microneedles array visualized at 75X
magnification.
5.3.5. In vitro permeation studies of iron dextran from soluble microneedles
From the in vitro transport studies after insertion of microneedlesin hairless rat skin, there
was a lag time of 2 hours was observed. A cumulative amount of 15.66 ± 0.87 μg/cm 2 was
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permeated in 24 hours from microneedle array with ~260 μg iron and 20.64 ± 1.84 μg/cm 2 was
permeated from arrays having ~430 μg respectively. The amount of iron retained in the skin at
the active array application site was ~0.32 ± 0.04 µg/mg with microneedle array containing ~260
μg iron and ~0.45 ± 0.07 µg/mg with microneedle array containing ~430 μg iron.
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Figure 5-5. The cumulative amount of iron dextran permeated across rat skin from soluble
microneedles with ~260 µg of iron (♦) and with ~ 430 µg of iron (■). The data points represented
are the average of n= 6 ± S.D.
5.3.6. In vivo studies using soluble microneedles
There was a significant increase in the serum iron and % TS after 12 hours of application
of the soluble microneedle array to rats compared to the control group. The microneedle array
was applied for 12 hours and blood samples were collected for 24 hours. From in vitro studies
there was a 2 hour lag time for the drug release into the receiver fluid. In case of in vivo studies
the microneedle array was applied for 12 hours and the total serum iron concentration started
improving after 6 hours with a maximum concentration of 208.45± 18.46(µg/dl) detected at 24
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hours. The %TS was increased from 48.60 ± 6.77 (at 6 hours) to 65.20± 8.7 (at 24 hours). The
iron dextran retained in the biopsied section of rat skin after in vivo studies was ~0.36 ± 0.08
µg/mg (with an absolute amount of ~103.5 ± 8.3 µg in the tissue).
Iron carbohydrate complexes that are administered into the systemic circulationenters
into plasma and phagocytosed within reticuloendothelial system (RES). In RES, iron and
carbohydrate complex gets cleaved to generate free iron and stored as ferritin in
reticuloendothelial iron pool or transported away by iron export protein ferroportin, and iron gets
exchanges with transferrin [115]. The circulating transferrin carries iron to various metabolic
pools and bone marrow for erythropoiesis. From a previous study by Henderson et al, after
intravenous infusions of radiolabelled iron dextran at different dose strengths (100-2000 mg),
iron was detected in the RES within few hours and the administered iron getting cleared from
plasma into RES in 4-10 days based on the dose strength administered [141]. In the present
study, the iron dextran might be releasing slowly from the soluble microneedles and entering into
the systemic circulation which might be eventually picked up by RES to release iron from the
iron dextran complex.
Biochemical
parameters

Time (h)
Basal
values
156.15 ±
27.30

3

6

12

18

24

162.05 ±
3.36

161.2
±18.95

179.45 ±
8.27

190.9 ±
10.87

208.45 ±
18.46

TIBC (µg/dl)

320.39 ±
11.51

349.55 ±
5.28

347.75 ±
12.52

313.35 ±
6.86

306.55 ±
8.27

319.02 ±
17.82

%TS

48.60 ±
6.77

46.79 ±
8.55

46.48 ±
7.12

57.31 ±
3.89

62.24 ±
1.87

65.20 ±
8.7

Serum
Iron(µg/dl)

Table 5-2. The mean biochemical parameters measured at different time points. Iron dextran
soluble microneedle array (430 µg of iron) was inserted into the rat abdominal skin for 12 hours
and blood sample were collected till 24 hours. The values represented are the average of n= 3 ±
S.D.
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5.3.7. Cell culture studies
5.3.7.1. Cell proliferation assay
MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium)]assay was performed to measure the mitochondrial activity of the cells after treating
the cells with iron dextran at different concentrations (10-0.31 mg/ml) and digitonin (60-1.87
µg/ml) (positive control)prepared at different concentration. The absorbance due to the formation
of colored formazan by the reduction of tetrazolium compound in presence of the cells was
measured at 490 nm. Cell proliferation studies were performed both in HEK and HDF cell lines.
In both the cell lines; cells treated with different concentrations of iron dextran exhibited very
high absorption. In a different study, the absorbance of iron dextran with basal media without
cells was measured in presence of MTS reagent and a background absorbance was observed with
iron dextran which might be due to the intense color of iron dextran. Due to the interference of
iron dextran at formazan absorption wavelength, MTS assay was not conclusive to determine the
cell viability in both the cell lines.
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Figure5-6A.
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HDF Cell Line-ID

Figure5-6B.
Figure5-6. The mitochondrial activity (MTS activity) of (A) HEK and (B) HDF cells after 24 h
exposure to 100 µl of iron dextran (10-0.31 mg/ml) and digitonin (60 µg/ml-1.87 µg/ml). Results
are combined from three independent exposures and expressed as mean (± S.D.).
5.3.7.2. ROS assay
From figure 5-7, the amount of DCF generated (in florescence units) was very low,
indicating that there was no ROS production after treating the cells with iron dextran at different
concentrations. In case of cells treated with hydrogen peroxide at different concentrations the
amount of DCF produced was high indicating the toxicity in these cell lines.
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Figure 5-7B.
Figure5-7. Induction of reactive oxygen species (ROS) by iron dextran (10-0.31 mg/ml) or
hydrogen peroxide in (A) HEK and (B) HDF cells after 24 h exposure. Results are combined
from three independent exposures and expressed as mean (± S.D.).
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5.3.7.3. Cytokines measurement
All the measured cytokines in this study were excretory proteins and any cytotoxic effect
of iron dextran on the cells can be detected by measuring and quantifying these cytokines.In
HEK cell lines, a dose dependent expression of IL-1α, IL-6 levels were observed after exposing
the cells to different concentrations of iron dextran. These observed cytokine concentrations
were very low compared to cytokines concentrations expressed with positive controls, hydrogen
peroxide and digitonin. In HDF cell lines, only a small concentration of IL-6 and MCP-1 were
observed with high concentrations of iron dextran (10 mg/ml and 5 mg/ ml). From the observed
results, iron dextran at these concentrations might be safe to both HEK and HDF cells with no
sign of excessive up-regulation of inflammatory markers.
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300
200
100
0
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IL-1a
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IL-4
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IL-13

MCP-1

IFNg

TNFa

Figure5-8. An overview of the amount of cytokines detected in HEK and HDF cell line after
treating them with iron dextran at different concentrations (1.25-10 mg/ml), H2O2 (1000 µM) and
digitonin (30 µg/ml). Results are combined from three independent exposures and expressed as
mean (± S.D.).
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Figure5-9. Presence of cytokines in (A) HEK and (B) HDF cells after 24 h exposure to 100 µl of
iron dextran (1.25-10 mg/ml) and hydrogen peroxide (1000 µM) and digitonin (30 µg/ml).
Results are combined from three independent exposures and expressed as mean (± S.D.).
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5.3. CONCLUSIONS
Transdermal delivery of therapeutic agents allows slow and prolonged delivery, which is
essential for delivering iron to avoid the saturation of transferrin and to control the free iron
stores in the systemic circulation. This study demonstrates the feasibility of microneedle based
transdermal delivery of iron dextran as one of the potential routes for iron replenishment. In the
preliminary studies the iron dextran delivered transdermally in the form of Poke and Patch
proved to be successful to treat iron deficiency anemia in anemic animal models. Further studies
with soluble microneedle system is likely to overcome the limitations of parenteral delivery of
iron dextran and is believed to be relatively more patient compliant due to minimal invasive
nature of the mode of delivery.
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